WO2011133751A2 - Process of producing cycloalkylcarboxamido-indole compounds - Google Patents

Process of producing cycloalkylcarboxamido-indole compounds Download PDF

Info

Publication number
WO2011133751A2
WO2011133751A2 PCT/US2011/033396 US2011033396W WO2011133751A2 WO 2011133751 A2 WO2011133751 A2 WO 2011133751A2 US 2011033396 W US2011033396 W US 2011033396W WO 2011133751 A2 WO2011133751 A2 WO 2011133751A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
aliphatic
organic solvent
ring
Prior art date
Application number
PCT/US2011/033396
Other languages
French (fr)
Other versions
WO2011133751A9 (en
WO2011133751A3 (en
Inventor
Gerald J. Tanoury
Cristian Harrison
Benjamin Joseph Littler
Peter Jamison Rose
Robert Michael Hughes
Young Chun Jung
David Andrew Siesel
Elaine Chungmin Lee
Daniel T. Belmont
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP11729195.5A priority Critical patent/EP2560954B1/en
Priority to US13/642,642 priority patent/US9035072B2/en
Priority to ES11729195.5T priority patent/ES2608474T3/en
Priority to KR1020127030452A priority patent/KR20130056244A/en
Priority to KR1020197015032A priority patent/KR20190061096A/en
Priority to CA2797118A priority patent/CA2797118C/en
Priority to CN201180031319.5A priority patent/CN103038214B/en
Priority to CA3108488A priority patent/CA3108488A1/en
Priority to AU2011242712A priority patent/AU2011242712B2/en
Priority to JP2013506299A priority patent/JP2013525371A/en
Priority to SG2012078374A priority patent/SG184987A1/en
Priority to MX2016009018A priority patent/MX353408B/en
Priority to NZ603721A priority patent/NZ603721A/en
Priority to RU2012149691/04A priority patent/RU2569678C2/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP18173910.3A priority patent/EP3381899B1/en
Priority to KR1020167010394A priority patent/KR101984225B1/en
Priority to BR112012027056A priority patent/BR112012027056B8/en
Priority to MX2015003252A priority patent/MX342288B/en
Priority to MX2012012204A priority patent/MX2012012204A/en
Publication of WO2011133751A2 publication Critical patent/WO2011133751A2/en
Publication of WO2011133751A3 publication Critical patent/WO2011133751A3/en
Publication of WO2011133751A9 publication Critical patent/WO2011133751A9/en
Priority to IL222539A priority patent/IL222539A0/en
Priority to IL236209A priority patent/IL236209B/en
Priority to US14/687,286 priority patent/US10071979B2/en
Priority to AU2016202569A priority patent/AU2016202569B2/en
Priority to US16/059,724 priority patent/US20190210991A1/en
Priority to IL268953A priority patent/IL268953B/en
Priority to US17/003,051 priority patent/US20210238158A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/74—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention features processes for preparing compounds useful for treating CFTR mediated diseases such as cystic fibrosis.
  • CFTR is a cAMP/ATP -mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • CFTR cystic fibrosis
  • a defect in this gene causes mutations in CFTR resulting in cystic fibrosis ("CF"), the most common fatal genetic disease in humans. Cystic fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + -ATPase pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • the present invention provides processes for preparing CFTR correctors useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.
  • Such compounds include (i?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3- dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1 H-indol-5 - yl)cyclopropanecarboxamide (hereinafter "Compound 1”) which has the structure below:
  • Compound 1 and pharmaceutically acceptable compositions thereof are useful for treating or lessening the severity of CFTR mediated diseases such as, for example, cystic fibrosis.
  • Compound 1 may exist in several different solid forms such as substantially crystalline forms or amorphous forms. DETAILED DESCRIPTION OF THE INVENTION
  • CFTR cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, AF508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
  • modulating means increasing or decreasing, e.g.
  • the term "chemically stable”, as used herein, means that the solid form of Compound 1 does not decompose into one or more different chemical compounds when subjected to specified conditions, e.g., 40 °C/75 % relative humidity, for a specific period of time. e.g. 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 decomposes, in some embodiments, less than about 20%>, less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 1%), less than about 0.5% of the form of Compound 1 decomposes under the conditions specified. In some embodiments, no detectable amount of the solid form of Compound 1 decomposes.
  • the term "physically stable”, as used herein, means that the solid form of Compound 1 does not change into one or more different physical forms of Compound 1 (e.g. different solid forms as measured by XRPD, DSC, etc.) when subjected to specific conditions, e.g., 40 °C/75 % relative humidity, for a specific period of time. e.g. 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 changes into one or more different physical forms when subjected to specified conditions.
  • specific conditions e.g. 40 °C/75 % relative humidity
  • less than about 20%, less than about 15%, less than about 10%, less than about 5%), less than about 3%, less than about 1%, less than about 0.5% of the solid form of Compound 1 changes into one or more different physical forms of Compound 1 when subjected to specified conditions. In some embodiments, no detectable amount of the solid form of Compound 1 changes into one or more physically different solid forms of Compound 1.
  • the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined.
  • the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations.
  • the term "about” or “approximately” means within 30%, 25%, 20%>, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • Compound 1, wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, probes in biological assays, or compounds with improved therapeutic profile.
  • protecting group abbreviated as P, as used herein refers to any chemical group introduced into a molecule by chemical modification of a functional group in order to obtain chemoselectivity in a subsequent chemical reaction.
  • Non-limiting examples of alcohol protecting groups include acetyl (Ac), benzoyl (Bz), benzyl (Bn), ⁇ - methoxyethoxymethyl ether (MEM), dimethoxytrityl (DMT), methoxymethyl ether (MOM), methoxytrityl (MMT), /?-methoxybenzyl ether (PMB), pivaloyl (Piv), tetrahydropyranyl (THP), trityl (Tr), and trimethylsilyl (TMS).
  • the protecting group is Bn which has the structure -CH 2 C 6 H 5 .
  • the abbreviation "DCM” stands for dichloromethane.
  • the abbreviation “IP A” stands for isopropyl alcohol.
  • the abbreviation “DMSO” stands for dimethylsulfoxide.
  • the abbreviation “MTBE” stands for methyl t-butyl ether.
  • the abbreviation “THF” stands for tetrahydrofuran.
  • the abbreviation “TEA” stands for triethylamine.
  • the abbreviation “dba” as in Pd(dba) 2 stands for dibenzylideneacetone.
  • the abbreviation “dpp ' as in Pd(dppf)Cl 2 stands for stands for l,l '-bis(diphenylphosphino) ferrocene.
  • the invention features a method for preparing a compound of formula I:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl,
  • -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , - COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • X is CN or C0 2 R
  • R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive; comprising the steps of
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic; m is an integer from 0 to 3 inclusive; and
  • Hal is a halide
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • X is CN or C0 2 R
  • R is R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive;
  • the invention features the above method wherein ring A is a fused heterocycloalkyl or heteroaryl. In another embodiment, ring A is selected from
  • the invention features the above method wherein X is CN. In another embodiment, X is C0 2 Et.
  • the invention features the above method wherein m is 0.
  • the invention features the above method wherein R J is a Ci_6 aliphatic. In another embodiment, R J is -CH 2 CH 3 .
  • the invention features the above method wherein Hal is
  • the invention features the above method wherein the first organic solvent is an aprotic solvent.
  • the first organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t- butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or
  • the first organic solvent is selected from
  • the first organic solvent is toluene.
  • the invention features the above method wherein step a) is carried out in the presence of a transition metal catalyst. In another embodiment, step a) is carried out in the presence of a palladium catalyst. In another embodiment, step a) is carried out in the presence of a palladium catalyst selected from palladium(II)acetate, Pd(dppf)Cl 2 , Pd(dba) 2 , tetrakis(triphenylphosphine)palladium(0) or
  • step a) is carried out in the presence of Pd(dba) 2 .
  • the invention features the above method wherein step a) is carried out at about 50 °C to 90 °C. In another embodiment, step a) is carried out at about 60 °C to 80 °C. In another embodiment, step a) is carried out at about 70 °C.
  • the invention features the above method wherein the second organic solvent is an aprotic solvent.
  • the second organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate,
  • the second organic solvent is dimethylsulfoxide .
  • the invention features the above method wherein step b) is carried out in the presence of an inorganic acid.
  • step b) is carried out in the presence of an inorganic acid selected from hydrochloric, sulfuric, nitric, phosphoric, or boric acid.
  • step b) is carried out in the presence of hydrochloric acid.
  • the invention features the above method wherein step b) is carried out at about 55 °C to 95 °C.
  • step b) is carried out at about 65 °C to 85 °C.
  • step b) is carried out at about 75 °C.
  • the invention features a method for preparing a compound of formula II:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Hal is a halide;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • n is an integer from 0 to 3 inclusive
  • n is an integer from 1 to 4 inclusive; comprising the steps of
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic; m is an integer from 0 to 3 inclusive; and
  • Hal is a halide
  • X is CN or C0 2 R
  • R is Ci_6 aliphatic or aryl
  • R J is hydrogen or Ci_ 6 aliphatic, to form a compound of formula IIC:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic;
  • X is CN or C0 2 R;
  • R is Ci_6 aliphatic or aryl
  • n is an integer from 0 to 3 inclusive; b) removing the -C0 2 R J group from compound IIC in a second organic solvent to form a compound of formula I:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • X is CN or C0 2 R
  • R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive;
  • Hal is a halide
  • q is an integer from 0 to 3 inclusive;
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • n is an integer from 0 to 3 inclusive
  • X is CN or C0 2 R
  • R is Ci_6 aliphatic or aryl
  • n is an integer from 1 to 4 inclusive;
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • n is an integer from 0 to 3 inclusive
  • n is an integer from 1 to 4 inclusive;
  • the invention features the above method wherein in step a), the first organic solvent is an aprotic solvent.
  • the first organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the first organic solvent is toluene.
  • the invention features the above method wherein in step a), m is 0.
  • the invention features the above method wherein in step a), Hal is Br.
  • the invention features the above method wherein in step a), ring A is a fused heterocyclic or heteroaryl ring. In another embodiment, ring A is selected In another embodiment, ring
  • the invention features the above method wherein in step a), X is CN. In another embodiment, X is C0 2 Et.
  • the invention features the above method wherein in step a) R J is Et.
  • the invention features the above method wherein in
  • the invention features the above method wherein in step b), the second solvent is an aprotic solvent.
  • the second solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t- butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or
  • the second solvent is dimethylsulfoxide.
  • the second solvent is dimethylsulfoxide.
  • the invention features the above method wherein in
  • the invention features the above method wherein in step c), the base is an inorganic base.
  • the base is a hydroxide.
  • the base is NaOH.
  • the invention features the above method wherein in formula IID, q is 1. [0049] In another embodiment, the invention features the above method wherein in formula IID, one Hal is CI and the other Hal is Br.
  • the invention features the above method wherein in step d), the base is NaOH. In another embodiment, in step d), the acid is HC1.
  • the invention features the above method wherein in step d), reaction with a hydroxide base takes place at about 60 °C to 100 °C.
  • reaction with a hydroxide takes place at about 70 °C to 90 °C. In another embodiment, reaction with a hydroxide takes place at about 80 °C.
  • the invention features the above method wherein in
  • the invention features the above method wherein in step e), the third organic solvent is an aprotic solvent.
  • the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the third organic solvent is toluene.
  • the invention features the above method wherein in step e), the halogenating agent is SOCl 2 .
  • the invention features the above method wherein step e) takes place at about 40 °C to 80 °C. In another embodiment, step e) takes place at about 50 °C to 70 °C. In another embodiment, step e) takes place at about 60 °C.
  • the invention features the above method wherein in
  • the invention features a method of preparing a compound of formula III:
  • R 2 is -R J , -OR J , -N(R J ) 2 , -NO 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_ 6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
  • P is a protecting group; and o is an integer from 0 to 3;
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3; with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • Hal is a halide
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -C haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • Hal is a halide
  • P is a protecting group
  • A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • Hal is a halide;
  • P is a protecting group
  • P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_ 6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III.
  • the invention features the above method wherein in formula IIIA, o is 1. In another embodiment, o is 1 and R 2 is F.
  • the invention features the above method wherein in step a), the halogenating reagent is N-bromosuccinimide.
  • the invention features the above method wherein in step a), the first organic solvent is an aprotic solvent.
  • the first organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the first organic solvent is ethyl acetate.
  • the invention features the above method wherein step a) takes place at about 2 °C to 42 °C. In another embodiment, step a) takes place at about 12 °C to 32 °C. In another embodiment, step a) takes place at about 22 °C. [0063] In another embodiment, the invention features the above method wherein in formula IIIB, o is 1, R 2 is F, and Hal is Br.
  • the invention features the above method wherein in formula IIIC, P is benzyl.
  • the invention features the above method wherein in step b), the second organic solvent is an aprotic solvent.
  • the second organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the second organic solvent is toluene.
  • the invention features the above method wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 70 °C to 90 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 80 °C.
  • the invention features the above method wherein in step b), reduction is carried out with hydrogen.
  • the invention features the above method wherein in step b) , the acid is p-toluenesulfonic acid.
  • the invention features the above method wherein in formula HID, o is 1, R 2 is F, Hal is Br, A " is Tos " , and P is benzyl.
  • the invention features the above method wherein in formula HIE, R 3 is C(CH 3 ) 2 CH 2 0(benzyl).
  • the invention features the above method wherein in step c) , the base is an inorganic base.
  • the invention features the above method wherein in step c), the base is NaHC0 3 .
  • the invention features the above method wherein in step d), the third organic solvent is an aprotic solvent.
  • the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the third organic solvent is acetonitrile.
  • step d) takes place at about 60 °C to 100 °C. In another embodiment, step d) takes place at about 70 °C to 90 °C. In another embodiment, step d) takes place at about 80 °C.
  • the invention features the above method wherein in step d), the catalyst is a palladium catalyst.
  • the catalyst in step d), is selected from palladium(II)acetate, Pd(dppf)Cl 2 , Pd(dba) 2 , (MeCN) 2 PdCl 2 ,
  • the catalyst in step d), is palladium(II)acetate.
  • the invention features a method of preparing a compound of formula IV:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri and R 2 is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_ 6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
  • P is a protecting group
  • n is an integer from 0 to 3 inclusive
  • n is an integer from 1 to 4 inclusive;
  • o is an integer from 1 to 3 inclusive
  • Pv 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -C haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3; and Hal is a halide;
  • R 2 is -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • Hal is a halide
  • P is a protecting group
  • A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
  • R 2 is -R J , -OR J , -N(R J ) 2 , -NO 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • o is an integer from 0 to 3;
  • Hal is a halide
  • R3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_ 6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III:
  • R 2 is -R J , -OR J , -N(R J ) 2 , -NO 2 , halogen, -CN, -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy,
  • R J is hydrogen or Ci_ 6 aliphatic
  • R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_ 6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
  • P is a protecting group
  • o is an integer from 0 to 3; e) reacting the compound of formula III in a fourth organic solvent with a compound of formula II:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Hal is a halide;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic;
  • m is an integer from 0 to 3 inclusive; and
  • n is an integer from 1 to 4 inclusive; to form the compound of formula IV.
  • the invention features the above method wherein in
  • the invention features the above method wherein in formula IV, m is 0. In another embodiment, in formula IV, n is 1. In another embodiment, in formula IV, o is 1 and R 2 is F.
  • the invention features the above method wherein in formula IV, P is benzyl.
  • the invention features the above method wherein in formula IV, R 3 is a C 4 aliphatic optionally substituted with OP. In another embodiment, in In another embodiment, in formula IV, R 3 is [0081] In another embodiment, the invention features the above method wherein in
  • the invention features the above method wherein in step a), the halogenating reagent is N-bromosuccinimide.
  • the invention features the above method wherein in step a) , the first organic solvent is an aprotic solvent.
  • the first organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the first organic solvent is ethyl acetate.
  • the invention features the above method wherein step a) takes place at about 2 °C to 42 °C. In another embodiment, step a) takes place at about 12 °C to 32 °C. In another embodiment, step a) takes place at about 22 °C.
  • the invention features the above method wherein in formula IIIB, o is 1, R 2 is F, and Hal is Br.
  • the invention features the above method wherein in formula IIIC, P is benzyl.
  • the invention features the above method wherein in step b) , the second organic solvent is an aprotic solvent.
  • the second organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the second organic solvent is toluene.
  • the invention features the above method wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 70 °C to 90 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 80 °C.
  • the invention features the above method wherein in step b), reduction is carried out with hydrogen.
  • the invention features the above method wherein in step b) , the acid is p-toluenesulfonic acid.
  • the invention features the above method wherein in formula HID, o is 1, R 2 is F, Hal is Br, A " is Tos " , and P is benzyl.
  • the invention features the above method wherein in formula HIE, R 3 is C(CH 3 ) 2 CH 2 0(benzyl).
  • the invention features the above method wherein in step c) , the base is an inorganic base.
  • the invention features the above method wherein in step c) , the base is NaHC0 3 .
  • the invention features the above method wherein in step d) , the third organic solvent is an aprotic solvent.
  • the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • step d) in step d), the third organic solvent is acetonitrile.
  • the invention features the above method wherein step d) takes place at about 60 °C to 100 °C. In another embodiment, step d) takes place at about 70 °C to 90 °C. In another embodiment, step d) takes place at about 80 °C.
  • the invention features the above method wherein in step d), the catalyst is a palladium catalyst.
  • the catalyst in step d), is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba) 2 ,
  • the catalyst in step d), is palladium(II)acetate.
  • the invention features the above method wherein in step
  • the invention features the above method wherein in step e), the fourth organic solvent is an aprotic solvent.
  • the fourth organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide.
  • the fourth organic solvent is dichloromethane.
  • the invention features the above method wherein step e) takes place at about -20 °C to 20 °C. In another embodiment, step e) takes place at about -10 °C to 10 °C. In another embodiment, step e) takes place at about 0 °C.
  • the invention features the above method wherein in step e), the compound of formula II is prepared in situ by halogenating the acid precursor and reacted with the compound of formula III without isolation.
  • the invention features the above method further comprising removing the two protecting groups from the compound of formula IV to form a compound of formula IVA:
  • the protecting groups are removed by hydrogenation.
  • the invention features a method of preparing Compound 1 :
  • the invention features the above method wherein in step a), the brominating agent is N-bromosuccinimide.
  • the invention features the above method wherein in setp b), the reduction is carried out with hydrogen.
  • the invention features the above method wherein in setp b), the base is an inorganic base.
  • the invention features the above method wherein in setp b), the base is NaHC0 3 .
  • the invention features the above method wherein in step c), the catalyst is a palladium catalyst.
  • the catalyst in step c), is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba) 2 ,
  • the catalyst is palladium(II)acetate.
  • the invention features the above method wherein in step d), compound 8 is made in situ by halogenating the acid precursor without isolation.
  • the invention features the above method wherein in step e), the Bn protecting groups are removed by hydrogenation.
  • the invention features a compound of formula 23:
  • ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • Ri is independently selected from -R J , -OR J , -N(R J ) 2 , -N0 2 , halogen, -CN,
  • -Ci_ 4 haloalkyl, -Ci_ 4 haloalkoxy, -C(0)N(R J ) 2 , -NR J C(0)R J , -SOR J , -S0 2 R J , -S0 2 N(R J ) 2 , -NR J S0 2 R J , -COR J , -C0 2 R J , -NR J S0 2 N(R J ) 2 , -COCOR J ;
  • R J is hydrogen or Ci_ 6 aliphatic
  • X is CN or C0 2 R
  • R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive.
  • the invention features a compound of formula 23 and the attendant definitions, wherein ring A is a fused heterocycloalkyl or heteroaryl.
  • ring A is .
  • the invention features a compound of formula 23 and the attendant definitions, wherein X is CN. In another embodiment, X is C0 2 Et. [00115] In another embodiment, the invention features a compound of formula 23 and the attendant definitions, wherein m is 0.
  • the invention features a compound of formula 23 and the attendant definitions, wherein R J is Ci_ 6 aliphatic. In another embodiment, R J is -CH 2 CH 3 .
  • the invention features the compound
  • the invention features the compound
  • aryl halide IA is reacted with ester IB in the presence of a transition metal catalyst in a suitable solvent (e.g. toluene) to produce ester IC.
  • a suitable solvent e.g. toluene
  • X can either be CN or C0 2 R.
  • Treatment of IC with an acid in a suitable solvent e.g.
  • IA is commercially available.
  • ring A is a 5 membered dioxyl ring.
  • Hal in IA is Br.
  • the reaction of IA and IIB takes place in toluene in the presence of a Pd(0) caystalyst, e.g. Pd(dba) 2 .
  • the reaction takes place in the presence of an alkyl phosphine, e.g. t- Bu 3 P and phosphate salt, e.g. Na 3 P0 4 .
  • the reaction of IA and IIB takes place at about 70 °C.
  • R J is Et.
  • the de-esterification of IC to I is done with an inorganic acid.
  • the inorganic acid is HC1.
  • the conversion takes place in an appropriate aprotic solvent (e.g. DMSO) at about 75 °C.
  • I is reacted with NaOH and an alkyl dihalide to yield the cycloalkylidene in a suitable solvent (e.g. MTBE).
  • a suitable solvent e.g. MTBE
  • the process is adaptable to several spirocyclic rings by choosing the appropriate alkyl dihalide.
  • a spirocylic butane ring can be produced by reacting I with, for example, l-bromo-3-chloropropane. It has been found that a mixed bromo and chloro dihalide works best on an economic scale as it is believed that the thermodynamics of the reaction are more favorable.
  • HE is hydrolized to the carboxylic acid IIF in the presence of water and a base (e.g. NaOH) in a suitable solvent (e.g. ethanol). Subseqent treatment with an acid such as HC1 yields IIF. In another embodiment, IIF is worked up by recrystallizing it from toluene.
  • a base e.g. NaOH
  • a suitable solvent e.g. ethanol
  • the halogenating agent that converts IIF to II is thionyl chloride.
  • the thionyl chloride is added to IIF in toluene at about 60 °C. In one embodiment, this step directly proceeds the coupling between II and amine III (see below) and is carried out in the same reaction vessel.
  • a halogenating agent
  • b Zn(II) catalyst
  • c H 2 , Pt
  • d acid
  • e base
  • f Pd(II) catalyst
  • R 2 , o, Hal, A , and P are defined as above.
  • R 2 is F and is meta to the amine group.
  • IIIA is brominated with N-bromosuccinimide in a suitable solvent (e.g.
  • IIIB is reacted with epoxide IIIC effecting a ring opening reaction with the amine group of IIIB to form HID.
  • the protecting group, P, in IIIC is benzyl (Bn).
  • epoxide IIIC is chiral.
  • IIIC is (R) IIIC.
  • IIIC is (S) IIIC.
  • the ring opening reaction is carried out in a suitable solvent (e.g. toluene) at about 80 °C.
  • the ring opening reaction takes place in the presence of a Zn(II) catalyst (e.g.
  • the conversion from IIIB to HID comprises the ring opening reaction with epoxide IIIC, followed by hydrogenation, and then treatment with an acid to form HID.
  • hydrogenation is carried out with H2/Pt(S)/C.
  • the acid is toluene sulfonic acid, such that A is a tosylate anion.
  • alkyne HIE is coupled with HID in a suitable solvent (e.g. acetonitrile) at about 80 °C.
  • the coupling reaction takes place in the presence of a Pd(II) catalyst, such as Pd(OAc) 2 .
  • the initial reaction does not result in ring closure, only replacement of the halide on HID.
  • Ring closure is accomplished through reaction with another Pd(II) catalyst, such as (MeCN) 2 PdCl 2 in a suitable solvent (e.g. acetonitrile).
  • ring closure takes place at about 80 °C.
  • R 3 in alkyne HIE is -C(CH 3 ) 2 CH 2 OBn.
  • the product from the coupling reaction is not isolated but taken up in acetonitrile and reacted with (MeCN) 2 PdCl 2 .
  • a halogenating agent
  • b aprotic solvent
  • dichloromethane (DCM)) yields the protected analog of Compound 1.
  • the acid halide II is prepared from IIF as depicted in Scheme 1 in the same reaction vessel and is not isolated.
  • the acid-based reaction is carried out in the presence of a base such as triethylamine (TEA).
  • TEA triethylamine
  • the amount of TEA is 2 equivalents relative to II.
  • water is added to the mixture and stirred for an additional 30 minutes.
  • the organic phase is separated and IV is isolated by distilling off the reaction solvent.
  • IV is collected by silica pad filtration.
  • compounds of formula IV may be deprotected to form compounds of formula IVa according to Scheme 4.
  • hydrogen pressurization is 3 Bars. In another embodiment, hydrogen pressurization is 3 Bars. In another
  • the hydrogenation agitation rate is increased to 800 rpm.
  • the hydrogenation vessel is heated to about 50 °C for 2 days.
  • more catalyst is added and hydrogenation continues for another 4 days.
  • IV is dissolved in a suitable solvent (e.g. THF).
  • Compound 1 may be prepared by coupling the acid halide moiety 7 with the amine moiety 8 to form compound 9 followed by deprotection according to Scheme 5.
  • compositions comprising Compound 1 Form A or amorphous Compound 1 as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
  • compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene -polyoxypropylene -block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin;
  • glycols such a propylene glycol or polyethylene glycol
  • esters such as ethyl oleate and ethyl laurate
  • agar buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
  • the present invention provides a method of treating a condition, disease, or disorder implicated by CFTR.
  • the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of CFTR activity, the method comprising administering a composition comprising a Compound 1 described herein to a subject, preferably a mammal, in need thereof.
  • a "CFTR-mediated disease” as used herein is a disease selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof
  • the present invention provides a method of treating a CFTR-mediated disease in a human comprising the step of administering to said human an effective amount of a composition comprising Compound 1 described herein.
  • an "effective amount" of Compound 1 Form A or amorphous Compound 1 or a pharmaceutically acceptable composition thereof is that amount effective for treating or lessening the severity of any of the diseases recited above.
  • Compound 1 or a pharmaceutically acceptable composition thereof may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases recited above.
  • compositions thereof are useful for treating or lessening the severity of cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia.
  • the presence of residual CFTR activity at the epithelial surface can be readily detected using methods known in the art, e.g., standard electrophysiological, biochemical, or histochemical techniques. Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary CI " concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be readily detected in patients heterozygous or homozygous for a variety of different mutations, including patients homozygous or heterozygous for the most common mutation, AF508.
  • Compound 1 described herein or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain genotypes exhibiting residual CFTR activity, e.g., class III mutations (impaired regulation or gating), class IV mutations (altered conductance), or class V mutations (reduced synthesis) (Lee R. Choo-Kang, Pamela L., Zeitlin, Type I, II, III, IV, and V cystic fibrosis Tansmembrane Conductance Regulator Defects and Opportunities of Therapy; Current Opinion in Pulmonary Medicine 6:521 - 529, 2000).
  • Other patient genotypes that exhibit residual CFTR activity include patients homozygous for one of these classes or heterozygous with any other class of mutations, including class I mutations, class II mutations, or a mutation that lacks classification.
  • Compound 1 described herein or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain clinical phenotypes, e.g., a moderate to mild clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of epithelia.
  • phenotypes include patients exhibiting pancreatic insufficiency or patients diagnosed with idiopathic pancreatitis and congenital bilateral absence of the vas deferens, or mild lung disease.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient or "subject”, as used herein, means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • the dosage amount of Compound 1 in the dosage unit form is from 100 mg to 1,000 mg. In another embodiment, the dosage amount of
  • Compound 1 is from 200 mg to 900 mg. In another embodiment, the dosage amount of Compound 1 is from 300 mg to 800 mg. In another embodiment, the dosage amount of Compound 1 is from 400 mg to 700 mg. In another embodiment, the dosage amount of Compound 1 is from 500 mg to 600 mg.
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • compositions for rectal or vaginal administration are preferably
  • suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Compound 1 described herein or a pharmaceutically acceptable composition thereof can be employed in combination therapies, that is, Compound 1 can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as "appropriate for the disease, or condition, being treated”.
  • the additional agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of the present invention, or a nutritional agent.
  • the additional therapeutic agent is an antibiotic.
  • antibiotics useful herein include tobramycin, including tobramycin inhaled powder (TIP), azithromycin, aztreonam, including the aerosolized form of aztreonam, amikacin, including liposomal formulations thereof, ciprofloxacin, including formulations thereof suitable for administration by inhalation, levoflaxacin, including aerosolized formulations thereof, and combinations of two antibiotics, e.g., fosfomycin and tobramycin.
  • TIP tobramycin inhaled powder
  • azithromycin aztreonam
  • aztreonam including the aerosolized form of aztreonam
  • amikacin including liposomal formulations thereof
  • ciprofloxacin including formulations thereof suitable for administration by inhalation
  • levoflaxacin including aerosolized formulations thereof
  • combinations of two antibiotics e.g., fosfomycin and tobramycin.
  • the additional agent is a mucolyte.
  • exemplary mucolytes useful herein includes Pulmozyme®.
  • the additional agent is a bronchodialator.
  • bronchodialtors include albuterol, metaprotenerol sulfate, pirbuterol acetate, salmeterol, or tetrabuline sulfate.
  • the additional agent is effective in restoring lung airway surface liquid. Such agents improve the movement of salt in and out of cells, allowing mucus in the lung airway to be more hydrated and, therefore, cleared more easily.
  • Exemplary such agents include hypertonic saline, denufosol tetrasodium ([[(3S, 5R)-5-(4-amino-2- oxopyrimidin-l-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5- (2,4-dioxopyrimidin- 1 -yl)-3 , 4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy- hydroxyphosphoryl] hydrogen phosphate), or bronchitol (inhaled formulation of mannitol).
  • the additional agent is an anti-inflammatory agent, i.e., an agent that can reduce the inflammation in the lungs.
  • agents useful herein include ibuprofen, docosahexanoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.
  • the additional agent is a CFTR modulator other than Compound 1, i.e., an agent that has the effect of modulating CFTR activity.
  • CFTR modulator other than Compound 1, i.e., an agent that has the effect of modulating CFTR activity.
  • agents include ataluren ("PTC 124®"; 3-[5-(2-fluorophenyl)-l,2,4-oxadiazol-3-yl]benzoic acid), sinapultide, lancovutide, depelestat (a human recombinant neutrophil elastase inhibitor), cobiprostone (7- ⁇ (2R, 4aR, 5R, 7aR)-2-[(3S)-l,l-difluoro-3-methylpentyl]-2-hydroxy-6- oxooctahydrocyclopenta[b]pyran-5-yl ⁇ heptanoic acid), and N-(5-hydroxy-2,4-ditert-butyl
  • the additional agent is a nutritional agent.
  • Exemplary nutritional agents include pancrelipase (pancreating enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase®, or Creon®, Liprotomase® (formerly Trizytek®), Aquadeks®, or glutathione inhalation.
  • the additional nutritional agent is pancrelipase.
  • the additional agent is a compound selected from gentamicin, curcumin, cyclophosphamide, 4-phenylbutyrate, miglustat, felodipine, nimodipine, Philoxin B, geniestein, Apigenin, cAMP/cGMP modulators such as rolipram, sildenafil, milrinone, tadalafil, amrinone, isoproterenol, albuterol, and almeterol, deoxyspergualin, HSP 90 inhibitors, HSP 70 inhibitors, proteosome inhibitors such as epoxomicin, lactacystin, etc.
  • the additional agent is a compound disclosed in WO 2004028480, WO 2004110352, WO 2005094374, WO 2005120497, or WO 2006101740.
  • the additiona agent is a benzo(c)quinolizinium derivative that exhibits CFTR modulation activity or a benzopyran derivative that exhibits CFTR modulation activity.
  • the addditional agent is a compound disclosed in US7202262, US6992096, US20060148864, US20060148863, US20060035943,
  • the additional agent is a compound disclosed in WO2004080972, WO2004111014, WO2005035514, WO2005049018, WO2006099256, WO2006127588, or WO2007044560.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • Vitride® sodium bis(2-methoxyethoxy)aluminum hydride
  • NaAlH 2 (OCH 2 CH 2 OCFl 3 ) 2 ], 65 wgt% solution in toluene) was purchased from Aldrich Chemicals.
  • 3-Fluoro-4-nitroaniline was purchased from Capot Chemicals.
  • 5-Bromo-2,2- difluoro- 1 ,3-benzodioxole was purchased from Alfa Aesar.
  • 2,2-Difluoro- 1 ,3-benzodioxole-5- carboxylic acid was purchased from Saltigo (an affiliate of the Lanxess Corporation).
  • a reactor was purged with nitrogen and charged with 900 mL of toluene. The solvent was degassed via nitrogen sparge for no less than 16 h. To the reactor was then charged Na 3 P0 4 (155.7 g, 949.5 mmol), followed by bis(dibenzylideneacetone) palladium (0) (7.28 g, 12.66 mmol). A 10% w/w solution of tert-butylphosphine in hexanes (51.23 g, 25.32 mmol) was charged over 10 min at 23 °C from a nitrogen purged addition funnel.
  • a stock solution of 50% w/w NaOH was degassed via nitrogen sparge for no less than 16 h.
  • An appropriate amount of MTBE was similarly degassed for several hours.
  • To a reactor purged with nitrogen was charged degassed MTBE (143 mL) followed by (2,2- difluoro- l,3-benzodioxol-5-yl)-acetonitrile (40.95 g, 207.7 mmol) and tetrabutylammonium bromide (2.25 g, 10.38 mmol).
  • the volume of the mixture was noted and the mixture was degassed via nitrogen sparge for 30 min. Enough degassed MTBE is charged to return the mixture to the original volume prior to degassing.
  • the aqueous phase was extracted with MTBE (123 mL), and the combined organic phase was washed with 1 N HC1 (163mL) and 5% NaCl (163 mL).
  • the solution of (2,2- difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarbonitrile in MTBE was concentrated to 164 mL under vacuum at 40 - 50 °C.
  • the solution was charged with ethanol (256 mL) and again concentrated to 164 mL under vacuum at 50 - 60 °C.
  • Ethanol (256 mL) was charged and the mixture concentrated to 164 mL under vacuum at 50 - 60 °C.
  • Toluene (328 mL) was charged and the mixture condensed to 164 mL at 70 - 75 °C.
  • the mixture was cooled to 45 °C, charged with MTBE (364 mL) and stirred at 60 °C for 20 min.
  • the solution was cooled to 25 °C and polish filtered to remove residual inorganic salts.
  • MTBE (123 mL) was used to rinse the reactor and the collected solids. The combined organics were transferred to a clean reactor in preparation for the next step.
  • the hydrogenator was charged with 5wt% Pt(S)/C (1.5 mol%>) and the mixture was stirred under N 2 at 30 °C (internal temperature). The reaction was flushed with N 2 followed by hydrogen. The hydrogenator pressure was adjusted to 1 Bar of hydrogen and the mixture was stirred rapidly (>1200 rpm). At the end of the reaction, the catalyst was filtered through a pad of Celite and washed with dichloromethane (10 vol). The filtrate was concentrated in vacuo. Any remaining isopropyl acetate was chased with dichloromethane (2 vol) and concentrated on a rotavap to dryness.
  • the aqueous phase (pH 9) was drained off and discarded. The remaining organic phase was washed with water (2 L, 2 vol). The organic phase was concentrated in vacuo using a 22 L rotary evaporator, providing the crude product as an orange oil.
  • Method B Magnesium turnings (106 g, 4.35 mol, 1.0 eq) were charged to a 22 L reactor and then suspended in THF (760 mL, 1 vol). The vessel was cooled in an ice-water bath such that the batch temperature reached 2 °C. A solution of the propargyl chloride (760 g, 4.35 mol, 1.0 equiv) in THF (4.5 L, 6 vol) was added slowly to the reactor. After 100 mL was added, the addition was stopped and the mixture stirred until a 13 °C exotherm was observed, indicating the Grignard reagent initiation.
  • the mixture is filtered through Celite and the cake is washed with acetonitrile.
  • a solvent swap into ethyl acetate (7.5 vol) is performed.
  • the ethyl acetate solution is washed with aqueous NH 3 -NH 4 CI solution (2 x 2.5 vol) followed by 10% brine (2.5 vol).
  • the ethyl acetate solution is then stirred with silica gel (1.8 wt eq) and Si-TMT (0.1 wt eq) for 6 h. After filtration, the resulting solution is concentrated down.
  • the residual oil is dissolved in DCM / heptane (4 vol) and then purified by column chromatography.
  • the acid chloride solution in toluene (1 vol) is added while maintaining the batch temperature below 10 °C.
  • the reaction progress is monitored by HPLC, and the reaction is usually complete within minutes. After warming to 25 °C, the reaction mixture is washed with 5% NaHC0 3 (3.5 vol), 1 M NaOH (3.5 vol) and 1 M HCl (5 vol).
  • Compound 1 may also be prepared by one of several synthetic routes disclosed in US published patent application US20090131492, incorporated herein by reference.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • Bath Solution #1 (in mM) NaCl 160, KC1 4.5, CaCl 2 2, MgCl 2 1,
  • Chloride-free bath solution Chloride salts in Bath Solution #1 are substituted with gluconate salts.
  • CC2-DMPE Prepared as a 10 mM stock solution in
  • DiSBAC 2 (3) Prepared as a 10 mM stock in DMSO and stored at -20°C.
  • NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for optical measurements of membrane potential.
  • the cells are maintained at 37 °C in 5% C0 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ - ⁇ , 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 °C before culturing at 27 °C for 24 hrs for the potentiator assay.
  • the cells are cultured at 27 °C or 37 °C with and without compounds for 16 - 24 hours.
  • the FRT epithelia demonstrated resistances of 4 ⁇ / cm 2 or more.
  • the solutions were maintained at 27 °C and bubbled with air.
  • the electrode offset potential and fluid resistance were corrected using a cell-free insert.
  • the current reflects the flow of CI " through AF508-CFTR expressed in the apical membrane.
  • the Isc was digitally acquired using an MP100A-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
  • Typical protocol utilized a basolateral to apical membrane CI " concentration gradient.
  • normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 ⁇ g/ml), whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large CI " concentration gradient across the epithelium.
  • All experiments were performed 30 min after nystatin permeabilization. Forskolin (10 ⁇ ) and all test compounds were added to both sides of the cell culture inserts. The efficacy of the putative AF508-CFTR potentiators was compared to that of the known potentiator, genistein.
  • Basolateral solution in mM: NaCl (135), CaCl 2 (1.2), MgCl 2 (1.2), K 2 HP0 4
  • Fisher rat epithelial (FRT) cells expressing AF508-CFTR wereg used for Ussing chamber experiments for the putative AF508-CFTR modulators identified from our optical assays.
  • the cells were cultured on Costar Snapwell cell culture inserts and cultured for five days at 37 °C and 5% C0 2 in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin. Prior to use for characterizing the potentiator activity of compounds, the cells were incubated at 27 °C for 16 - 48 hrs to correct for the AF508-CFTR. To determine the activity of corrections compounds, the cells were incubated at 27 °C or 37 °C with and without the compounds for 24 hours.
  • I AFSOS The macroscopic AF508-CFTR current (I AFSOS ) in temperature- and test compound- corrected NIH3T3 cells stably expressing AF508-CFTR were monitored using the perforated- patch, whole-cell recording.
  • voltage-clamp recordings of I AFSOS were performed at room temperature using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). All recordings were acquired at a sampling frequency of 10 kHz and low- pass filtered at 1 kHz. Pipettes had a resistance of 5 - 6 ⁇ when filled with the intracellular solution. Under these recording conditions, the calculated reversal potential for CI " (Eci) at room temperature was -28 mV.
  • the cells were incubated with 10 ⁇ of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 ⁇ of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C controls.
  • AF508-CFTR potentiators to increase the macroscopic AF508- CFTR CI " current (I AFSOS ) in NIH3T3 cells stably expressing AF508-CFTR was also investigated using perforated-patch-recording techniques.
  • the potentiators identified from the optical assays evoked a dose-dependent increase in I AFSOS with similar potency and efficacy observed in the optical assays.
  • the reversal potential before and during potentiator application was around -30 mV, which is the calculated EQ (-28 mV).
  • Intracellular solution in mM: Cs-aspartate (90), CsCl (50), MgCl 2 (1), HEPES
  • NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for whole- cell recordings.
  • the cells are maintained at 37 °C in 5% C0 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ - ⁇ , 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 °C for measuring the activity of correctors.
  • the inflow was placed adjacent to the patch, resulting in complete solution exchange within 1 - 2 sec.
  • the nonspecific phosphatase inhibitor F " (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents.
  • the pipette potential (V p ) was maintained at 80 mV.
  • Intracellular solution in mM: NMDG-C1 (150), MgCl 2 (2), EGTA (5), TES
  • NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for excised-membrane patch-clamp recordings.
  • the cells are maintained at 37 °C in 5% C0 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ - ⁇ , 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • 2,500 - 5,000 cells were seeded on poly-L-lysine- coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2- (1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5 -yl)cyclopropanecarboxamide (Compound 1 ), useful for treating CFTR mediated diseases such as cystic fibrosis.

Description

PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE
COMPOUNDS
CROSS REFERENCE TO RELATED APPLICATIONS
[001] This application claims priority to United States provisional patent application serial numbers 61/333,870, filed May 12, 2010; 61/327,095, filed April 22, 2010; 61/327,057, filed April 22, 2010; 61/329,493, filed April 29, 2010; 61/327,091, filed April 22, 2010;
61/329,510, filed April 29, 2010; 61/327,099, filed April 22, 2010; and 61/329,500, filed April 29, 2010, the entire contents of all applications are incorporated herein by reference.
TECHNICAL FIELD OF THE INVENTION
[002] The present invention features processes for preparing compounds useful for treating CFTR mediated diseases such as cystic fibrosis.
BACKGROUND OF THE INVENTION
[003] CFTR is a cAMP/ATP -mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
[004] The gene encoding CFTR has been identified and sequenced (See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P. et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989) Science 245: 1066-1073). A defect in this gene causes mutations in CFTR resulting in cystic fibrosis ("CF"), the most common fatal genetic disease in humans. Cystic fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
[005] In patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from
gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death. In addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the CF associated gene, individuals with a single copy of the CF associated gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea - perhaps explaining the relatively high frequency of the CF gene within the population.
[006] Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61 :863:870; and Kerem, B-S. et al. (1989) Science 245: 1073-1080; Kerem, B- S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, > 1000 disease causing mutations in the CF gene have been identified (http ://www . gene t . sickkids . on. ca/cftr/) . The most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as AF508-CFTR. This mutation occurs in
approximately 70% of the cases of cystic fibrosis and is associated with a severe disease. Other mutations include the Rl 17H and G551D.
[007] The deletion of residue 508 in AF508-CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to exit the ER, and traffic to the plasma membrane. As a result, the number of channels present in the membrane is far less than observed in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies have shown, however, that the reduced numbers of AF508-CFTR in the membrane are functional, albeit less than wild-type CFTR. (Dalemans et al. (1991), Nature Lond. 354: 526- 528; Denning et al, supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to AF508-CFTR, other disease causing mutations in CFTR that result in defective trafficking, synthesis, and/or channel gating could be up- or down-regulated to alter anion secretion and modify disease progression and/or severity.
[008] Although CFTR transports a variety of molecules in addition to anions, it is clear that this role (the transport of anions) represents one element in an important mechanism of transporting ions and water across the epithelium. The other elements include the epithelial Na+ channel, ENaC, Na+/2C17K+ co-transporter, Na+-K+-ATPase pump and the basolateral membrane K+ channels, that are responsible for the uptake of chloride into the cell.
[009] These elements work together to achieve directional transport across the epithelium via their selective expression and localization within the cell. Chloride absorption takes place by the coordinated activity of ENaC and CFTR present on the apical membrane and the Na -K -ATPase pump and CI- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via CI" channels, resulting in a vectorial transport. Arrangement of Na+/2C17K+ co-transporter, Na+-K+-ATPase pump and the basolateral membrane K+ channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride.
[0010] As discussed above, it is believed that the deletion of residue 508 in AF508- CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane. As a result, insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced. Infact, this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery, has been shown to be the underlying basis not only for CF disease, but for a wide range of other isolated and inherited diseases. The two ways that the ER machinery can malfunction is either by loss of coupling to ER export of the proteins leading to degradation, or by the ER accumulation of these defective/misfolded proteins [Aridor M, et al, Nature Med., 5(7), pp 745- 751 (1999); Shastry, B.S., et al,
Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J., et al., Swiss Med Wkly, 132, pp 211-222 (2002); Morello, JP et al, TIPS, 21, pp. 466- 469 (2000); Brass P., et al, Human Mut., 14, PP- 186-198 (1999)].
[0011] (i?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6- fluora-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide is disclosed in US published patent application US20090131492 (said publication being incorporated herein by reference in its entirety) as a modulator of CFTR activity and thus useful in treating CFTR-mediated diseases such as cystic fibrosis. There remains, however, a need for economical processes for the preparation of the cycloalkylcarboxamido-indole compounds described herein.
SUMMARY OF THE INVENTION
[0012] As described herein, the present invention provides processes for preparing CFTR correctors useful in the treatment of CFTR mediated diseases, such as cystic fibrosis. Such compounds include (i?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3- dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1 H-indol-5 - yl)cyclopropanecarboxamide (hereinafter "Compound 1") which has the structure below:
Figure imgf000005_0001
Compound 1
[0013] Compound 1 and pharmaceutically acceptable compositions thereof are useful for treating or lessening the severity of CFTR mediated diseases such as, for example, cystic fibrosis. Compound 1 may exist in several different solid forms such as substantially crystalline forms or amorphous forms. DETAILED DESCRIPTION OF THE INVENTION
[0014] Definitions
[0015] As used herein, the following definitions shall apply unless otherwise indicated.
[0016] The term "CFTR" as used herein means cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, AF508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
[0017] The term "modulating" as used herein means increasing or decreasing, e.g.
activity, by a measurable amount.
[0018] The term "chemically stable", as used herein, means that the solid form of Compound 1 does not decompose into one or more different chemical compounds when subjected to specified conditions, e.g., 40 °C/75 % relative humidity, for a specific period of time. e.g. 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 decomposes, in some embodiments, less than about 20%>, less than about 15%, less than about 10%, less than about 5%, less than about 3%, less than about 1%), less than about 0.5% of the form of Compound 1 decomposes under the conditions specified. In some embodiments, no detectable amount of the solid form of Compound 1 decomposes.
[0019] The term "physically stable", as used herein, means that the solid form of Compound 1 does not change into one or more different physical forms of Compound 1 (e.g. different solid forms as measured by XRPD, DSC, etc.) when subjected to specific conditions, e.g., 40 °C/75 % relative humidity, for a specific period of time. e.g. 1 day, 2 days, 3 days, 1 week, 2 weeks, or longer. In some embodiments, less than 25% of the solid form of Compound 1 changes into one or more different physical forms when subjected to specified conditions. In some embodiments, less than about 20%, less than about 15%, less than about 10%, less than about 5%), less than about 3%, less than about 1%, less than about 0.5% of the solid form of Compound 1 changes into one or more different physical forms of Compound 1 when subjected to specified conditions. In some embodiments, no detectable amount of the solid form of Compound 1 changes into one or more physically different solid forms of Compound 1. [0020] As used herein, the terms "about" and "approximately", when used in connection with doses, amounts, or weight percent of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. Specifically the term "about" or "approximately" means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" or "approximately" means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term "about" or "approximately" means within 30%, 25%, 20%>, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
[0021] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single
stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or
conformational) mixtures of the present compounds are within the scope of the invention. All tautomeric forms of the Compound 1 are included herein. For example, Compound 1 may exist as tautomers, both of which are included herein:
Figure imgf000007_0001
[0022] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, Compound 1, wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or compounds with improved therapeutic profile. [0023] The term "protecting group," abbreviated as P, as used herein refers to any chemical group introduced into a molecule by chemical modification of a functional group in order to obtain chemoselectivity in a subsequent chemical reaction. Non-limiting examples of alcohol protecting groups include acetyl (Ac), benzoyl (Bz), benzyl (Bn), β- methoxyethoxymethyl ether (MEM), dimethoxytrityl (DMT), methoxymethyl ether (MOM), methoxytrityl (MMT), /?-methoxybenzyl ether (PMB), pivaloyl (Piv), tetrahydropyranyl (THP), trityl (Tr), and trimethylsilyl (TMS). In one embodiment, the protecting group is Bn which has the structure -CH2C6H5.
[0024] The abbreviation "DCM" stands for dichloromethane. The abbreviation "IP A" stands for isopropyl alcohol. The abbreviation "DMSO" stands for dimethylsulfoxide. The abbreviation "MTBE" stands for methyl t-butyl ether. The abbreviation "THF" stands for tetrahydrofuran. The abbreviation "TEA" stands for triethylamine. The abbreviation "dba" as in Pd(dba)2 stands for dibenzylideneacetone. The abbreviation "dpp ' as in Pd(dppf)Cl2 stands for stands for l,l '-bis(diphenylphosphino) ferrocene.
[0025] In one aspect, the invention features a method for preparing a compound of formula I:
Figure imgf000008_0001
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl,
-Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, - CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive; comprising the steps of
a) reacting a compound of formula IA in a first organic solvent
Figure imgf000009_0001
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; m is an integer from 0 to 3 inclusive; and
Hal is a halide;
with a compound of formula IB:
Figure imgf000009_0002
IB wherein R is hydrogen or Ci_6 aliphatic, to form a compound of formula IC:
Figure imgf000009_0003
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive; and
b) removing the -C02RJ group from compound IC in a second organic solvent to form a compound of formula I.
[0026] In another embodiment, the invention features the above method wherein ring A is a fused heterocycloalkyl or heteroaryl. In another embodiment, ring A is selected from
[0027] In another embodiment, the invention features the above method wherein X is CN. In another embodiment, X is C02Et.
[0028] In another embodiment, the invention features the above method wherein m is 0.
[0029] In another embodiment, the invention features the above method wherein RJ is a Ci_6 aliphatic. In another embodiment, RJ is -CH2CH3.
[0030] In another embodiment, the invention features the above method wherein Hal is
Br. [0031] In another embodiment, the invention features the above method wherein the first organic solvent is an aprotic solvent. In another embodiment, the first organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t- butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or
dimethylsulfoxide. In another embodiment, the first organic solvent is selected from
acetonitrile, toluene, benzene, or xylenes. In another embodiment, the first organic solvent is toluene.
[0032] In another embodiment, the invention features the above method wherein step a) is carried out in the presence of a transition metal catalyst. In another embodiment, step a) is carried out in the presence of a palladium catalyst. In another embodiment, step a) is carried out in the presence of a palladium catalyst selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2, tetrakis(triphenylphosphine)palladium(0) or
tris(dibenzylideneacetone)dipalladium(0). In another embodiment, step a) is carried out in the presence of Pd(dba)2.
[0033] In another embodiment, the invention features the above method wherein step a) is carried out at about 50 °C to 90 °C. In another embodiment, step a) is carried out at about 60 °C to 80 °C. In another embodiment, step a) is carried out at about 70 °C.
[0034] In another embodiment, the invention features the above method wherein the second organic solvent is an aprotic solvent. In another embodiment, the second organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate,
dichloromethane, or dimethylsulfoxide. In another embodiment, the second organic solvent is dimethylsulfoxide .
[0035] In another embodiment, the invention features the above method wherein step b) is carried out in the presence of an inorganic acid. In another embodiment, step b) is carried out in the presence of an inorganic acid selected from hydrochloric, sulfuric, nitric, phosphoric, or boric acid. In another embodiment, step b) is carried out in the presence of hydrochloric acid. [0036] In another embodiment, the invention features the above method wherein step b) is carried out at about 55 °C to 95 °C. In another embodiment, step b) is carried out at about 65 °C to 85 °C. In another embodiment, step b) is carried out at about 75 °C.
[0037] In another aspect, the invention features a method for preparing a compound of formula II:
Figure imgf000012_0001
II wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Hal is a halide;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; comprising the steps of
a) reacting a compound of formula IIA in a first organic solvent
Figure imgf000012_0002
IIA wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; m is an integer from 0 to 3 inclusive; and
Hal is a halide;
with a compound of formula IIB:
Figure imgf000013_0001
IIB wherein
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
RJ is hydrogen or Ci_6 aliphatic, to form a compound of formula IIC:
Figure imgf000013_0002
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
m is an integer from 0 to 3 inclusive; b) removing the -C02RJ group from compound IIC in a second organic solvent to form a compound of formula I:
Figure imgf000014_0001
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive;
c) reacting a compound of formula I with a compound of formula IID in the presence of a base:
Figure imgf000014_0002
IID
wherein, independently for each occurrence: Hal is a halide; and
q is an integer from 0 to 3 inclusive; to produce a compound of formula HE:
Figure imgf000015_0001
HE
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
n is an integer from 1 to 4 inclusive;
d) sequentially reacting a compound of formula HE with a hydroxide base and acid to form a compound of formula IIF:
Figure imgf000015_0002
IIF
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; and
e) reacting a compound of formula IIF with a halogenating agent in a third organic solvent to form a compound of formula II.
[0038] In another embodiment, the invention features the above method wherein in step a), the first organic solvent is an aprotic solvent. In another embodiment, the first organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, the first organic solvent is toluene.
[0039] In another embodiment, the invention features the above method wherein in step a), m is 0.
[0040] In another embodiment, the invention features the above method wherein in step a), Hal is Br.
[0041] In another embodiment, the invention features the above method wherein in step a), ring A is a fused heterocyclic or heteroaryl ring. In another embodiment, ring A is selected
Figure imgf000016_0001
In another embodiment, ring
Figure imgf000017_0001
[0042] In another embodiment, the invention features the above method wherein in step a), X is CN. In another embodiment, X is C02Et.
[0043] In another embodiment, the invention features the above method wherein in step a) RJ is Et.
[0044] In another embodiment, the invention features the above method wherein in
formula IIC, ring
Figure imgf000017_0002
is 0, X is CN, and RJ is Et.
[0045] In another embodiment, the invention features the above method wherein in step b), the second solvent is an aprotic solvent. In another embodiment, the second solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t- butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or
dimethylsulfoxide. In another embodiment, the second solvent is dimethylsulfoxide.
[0046] In another embodiment, the invention features the above method wherein in
Figure imgf000017_0003
[0047] In another embodiment, the invention features the above method wherein in step c), the base is an inorganic base. In another embodiment, the base is a hydroxide. In another embodiment, the base is NaOH.
[0048] In another embodiment, the invention features the above method wherein in formula IID, q is 1. [0049] In another embodiment, the invention features the above method wherein in formula IID, one Hal is CI and the other Hal is Br.
[0050] In another embodiment, the invention features the above method wherein in step d), the base is NaOH. In another embodiment, in step d), the acid is HC1.
[0051] In another embodiment, the invention features the above method wherein in step d), reaction with a hydroxide base takes place at about 60 °C to 100 °C. In another
embodiment, reaction with a hydroxide takes place at about 70 °C to 90 °C. In another embodiment, reaction with a hydroxide takes place at about 80 °C.
[0052] In another embodiment, the invention features the above method wherein in
formula HE, ring
Figure imgf000018_0001
, m is 0, n is 1 , and X is CN.
[0053] In another embodiment, the invention features the above method wherein in step e), the third organic solvent is an aprotic solvent. In another embodiment, in step e), the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step e), the third organic solvent is toluene.
[0054] In another embodiment, the invention features the above method wherein in step e), the halogenating agent is SOCl2.
[0055] In another embodiment, the invention features the above method wherein step e) takes place at about 40 °C to 80 °C. In another embodiment, step e) takes place at about 50 °C to 70 °C. In another embodiment, step e) takes place at about 60 °C.
[0056] In another embodiment, the invention features the above method wherein in
formula IIF, ring
Figure imgf000018_0002
is 0, and n is 1. [0057] In another embodiment, the invention features the above method wherein in
formula II,
Figure imgf000019_0001
s 0, n is 1 , and Hal is CI.
[0058] In another aspect, the invention features a method of preparing a compound of formula III:
Figure imgf000019_0002
III wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -NO2, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group; and o is an integer from 0 to 3;
comprising the steps of: a) reacting a compound of formula IIIA:
Figure imgf000019_0003
IIIA wherein, independently for each occurrence: R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; and
o is an integer from 0 to 3; with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:
Figure imgf000020_0001
wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; and
Hal is a halide;
b) reacting the compound of formula IIIB in a second organic solvent with a compound of formula IIIC:
IIIC
wherein:
P is a protecting group; followed by reduction and treatment with acid to form a compound of formula HID:
Figure imgf000021_0001
HID wherein:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -C haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3;
Hal is a halide;
P is a protecting group; and
Θ
A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
Figure imgf000021_0002
IIID-a wherein
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; Hal is a halide; and
P is a protecting group;
d) reacting a compound of formula IIID-a in a third organic solvent with a compound of formula HIE:
Figure imgf000022_0001
HIE
wherein, independently for each occurrence:
P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III.
[0059] In another embodiment, the invention features the above method wherein in formula IIIA, o is 1. In another embodiment, o is 1 and R2 is F.
[0060] In another embodiment, the invention features the above method wherein in step a), the halogenating reagent is N-bromosuccinimide.
[0061] In another embodiment, the invention features the above method wherein in step a), the first organic solvent is an aprotic solvent. In another embodiment, the first organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, the first organic solvent is ethyl acetate.
[0062] In another embodiment, the invention features the above method wherein step a) takes place at about 2 °C to 42 °C. In another embodiment, step a) takes place at about 12 °C to 32 °C. In another embodiment, step a) takes place at about 22 °C. [0063] In another embodiment, the invention features the above method wherein in formula IIIB, o is 1, R2 is F, and Hal is Br.
[0064] In another embodiment, the invention features the above method wherein in formula IIIC, P is benzyl.
[0065] In another embodiment, the invention features the above method wherein in step b), the second organic solvent is an aprotic solvent. In another embodiment, in step b), the second organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step b), the second organic solvent is toluene.
[0066] In another embodiment, the invention features the above method wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 70 °C to 90 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 80 °C.
[0067] In another embodiment, the invention features the above method wherein in step b), reduction is carried out with hydrogen.
[0068] In another embodiment, the invention features the above method wherein in step b) , the acid is p-toluenesulfonic acid.
[0069] In another embodiment, the invention features the above method wherein in formula HID, o is 1, R2 is F, Hal is Br, A" is Tos", and P is benzyl.
[0070] In another embodiment, the invention features the above method wherein in formula HIE, R3 is C(CH3)2CH20(benzyl).
[0071] In another embodiment, the invention features the above method wherein in step c) , the base is an inorganic base.
[0072] In another embodiment, the invention features the above method wherein in step c), the base is NaHC03. [0073] In another embodiment, the invention features the above method wherein in step d), the third organic solvent is an aprotic solvent. In another embodiment, in step d), the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step d), the third organic solvent is acetonitrile.
[0074] In another embodiment, the invention features the above method wherein step d) takes place at about 60 °C to 100 °C. In another embodiment, step d) takes place at about 70 °C to 90 °C. In another embodiment, step d) takes place at about 80 °C.
[0075] In another embodiment, the invention features the above method wherein in step d), the catalyst is a palladium catalyst. In another embodiment, in step d), the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2, (MeCN)2PdCl2,
tetrakis(triphenylphosphine)palladium(0) or tris(dibenzylideneacetone)dipalladium(0). In another embodiment, in step d), the catalyst is palladium(II)acetate.
[0076] In another aspect, the invention features a method of preparing a compound of formula IV:
Figure imgf000024_0001
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri and R2 is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group;
m is an integer from 0 to 3 inclusive;
n is an integer from 1 to 4 inclusive; and
o is an integer from 1 to 3 inclusive;
comprising the steps of:
a) reacting a compound of formula IIIA:
Figure imgf000025_0001
IIIA
wherein, independently for each occurrence:
Pv2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -C haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NPvJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; and
o is an integer from 0 to 3;
with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:
Figure imgf000025_0002
IIIB
wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; and Hal is a halide;
b) reacting the compound of formula IIIB in a second organic solvent with a compound of formula IIIC:
IIIC
wherein:
P is a protecting group; followed by reduction and treatment with acid to form a compound of formula HID:
Figure imgf000026_0001
HID
wherein:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3;
Hal is a halide;
P is a protecting group; and
Θ
A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
Figure imgf000027_0001
IIID-a
wherein:
R2 is -RJ, -ORJ, -N(RJ)2, -NO2, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3;
Hal is a halide; and
P is a protecting group; d) reacting a compound of formula HID in a third organic solvent with a compound of formula HIE:
Figure imgf000027_0002
HIE
wherein, independently for each occurrence:
R3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III:
Figure imgf000028_0001
III
wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -NO2, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group; and
o is an integer from 0 to 3; e) reacting the compound of formula III in a fourth organic solvent with a compound of formula II:
Figure imgf000028_0002
II
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Hal is a halide;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic; m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; to form the compound of formula IV.
0077 In another embodiment, the invention features the above method wherein in
Figure imgf000029_0001
[0078] In another embodiment, the invention features the above method wherein in formula IV, m is 0. In another embodiment, in formula IV, n is 1. In another embodiment, in formula IV, o is 1 and R2 is F.
[0079] In another embodiment, the invention features the above method wherein in formula IV, P is benzyl.
[0080] In another embodiment, the invention features the above method wherein in formula IV, R3 is a C4 aliphatic optionally substituted with OP. In another embodiment, in In another embodiment, in formula IV, R3 is
Figure imgf000029_0002
[0081] In another embodiment, the invention features the above method wherein in
is 0, n is 1 , o is 1 and R2 is F, P is benzyl, and R3 is
Figure imgf000030_0001
[0082] In another embodiment, the invention features the above method wherein in step a), the halogenating reagent is N-bromosuccinimide.
[0083] In another embodiment, the invention features the above method wherein in step a) , the first organic solvent is an aprotic solvent. In another embodiment, in step a), the first organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step a), the first organic solvent is ethyl acetate.
[0084] In another embodiment, the invention features the above method wherein step a) takes place at about 2 °C to 42 °C. In another embodiment, step a) takes place at about 12 °C to 32 °C. In another embodiment, step a) takes place at about 22 °C.
[0085] In another embodiment, the invention features the above method wherein in formula IIIB, o is 1, R2 is F, and Hal is Br.
[0086] In another embodiment, the invention features the above method wherein in formula IIIC, P is benzyl.
[0087] In another embodiment, the invention features the above method wherein in step b) , the second organic solvent is an aprotic solvent. In another embodiment, in step b), the second organic solvent is selected from 1 ,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step b), the second organic solvent is toluene.
[0088] In another embodiment, the invention features the above method wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 70 °C to 90 °C. In another embodiment, in step b), the reaction with a compound of formula IIIC takes place at about 80 °C.
[0089] In another embodiment, the invention features the above method wherein in step b), reduction is carried out with hydrogen.
[0090] In another embodiment, the invention features the above method wherein in step b) , the acid is p-toluenesulfonic acid.
[0091] In another embodiment, the invention features the above method wherein in formula HID, o is 1, R2 is F, Hal is Br, A" is Tos", and P is benzyl.
[0092] In another embodiment, the invention features the above method wherein in formula HIE, R3 is C(CH3)2CH20(benzyl).
[0093] In another embodiment, the invention features the above method wherein in step c) , the base is an inorganic base.
[0094] In another embodiment, the invention features the above method wherein in step c) , the base is NaHC03.
[0095] In another embodiment, the invention features the above method wherein in step d) , the third organic solvent is an aprotic solvent. In another embodiment, in step d), the third organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N- dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step d), the third organic solvent is acetonitrile. [0096] In another embodiment, the invention features the above method wherein step d) takes place at about 60 °C to 100 °C. In another embodiment, step d) takes place at about 70 °C to 90 °C. In another embodiment, step d) takes place at about 80 °C.
[0097] In another embodiment, the invention features the above method wherein in step d), the catalyst is a palladium catalyst. In another embodiment, in step d), the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2,
tetrakis(triphenylphosphine)palladium(0) or tris(dibenzylideneacetone)dipalladium(0). In another embodiment, in step d), the catalyst is palladium(II)acetate.
[0098] In another embodiment, the invention features the above method wherein in step
Figure imgf000032_0001
[0099] In another embodiment, the invention features the above method wherein in step e), the fourth organic solvent is an aprotic solvent. In another embodiment, in step e), the fourth organic solvent is selected from 1,2-dimethoxyethane, dioxane, acetonitrile, toluene, benzene, xylenes, methyl t-butyl ether, methyl ethyl ketone, methyl isobutyl ketone, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, ethyl acetate, dichloromethane, or dimethylsulfoxide. In another embodiment, in step e), the fourth organic solvent is dichloromethane.
[00100] In another embodiment, the invention features the above method wherein step e) takes place at about -20 °C to 20 °C. In another embodiment, step e) takes place at about -10 °C to 10 °C. In another embodiment, step e) takes place at about 0 °C.
[00101] In another embodiment, the invention features the above method wherein in step e), the compound of formula II is prepared in situ by halogenating the acid precursor and reacted with the compound of formula III without isolation.
[00102] In another embodiment, the invention features the above method further comprising removing the two protecting groups from the compound of formula IV to form a compound of formula IVA:
Figure imgf000033_0001
IVA.
[00103] In another embodiment, the protecting groups are removed by hydrogenation.
[00104] In another aspect, the invention features a method of preparing Compound 1 :
Figure imgf000033_0002
comprising the steps of:
a) reacting compound 2:
Figure imgf000033_0003
with a brominating reagent to form a compound 3 :
Figure imgf000033_0004
3
b) reacting compound 3 with compound 4:
Figure imgf000033_0005
followed by reduction to form compound 5 :
Figure imgf000034_0001
followed by neutralizing compound 5 with a base to give compound 5a:
Figure imgf000034_0002
5a
c) reacting compound 5awith compound 6:
Figure imgf000034_0003
in the presence of a catalyst to form compound 7:
Figure imgf000034_0004
d) reacting compound 7 with compound 8:
Figure imgf000034_0005
to form compound 9:
Figure imgf000035_0001
9 and
e) removing the two Bn protecting groups to form Compound 1.
[00105] In another embodiment, the invention features the above method wherein in step a), the brominating agent is N-bromosuccinimide.
[00106] In another embodiment, the invention features the above method wherein in setp b), the reduction is carried out with hydrogen.
[00107] In another embodiment, the invention features the above method wherein in setp b), the base is an inorganic base.
[00108] In another embodiment, the invention features the above method wherein in setp b), the base is NaHC03.
[00109] In another embodiment, the invention features the above method wherein in step c), the catalyst is a palladium catalyst. In another embodiment, in step c), the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2,
tetrakis(triphenylphosphine)palladium(0) or tris(dibenzylideneacetone)dipalladium(0). In another embodiment, in step c), the catalyst is palladium(II)acetate.
[00110] In another embodiment, the invention features the above method wherein in step d), compound 8 is made in situ by halogenating the acid precursor without isolation.
[00111] In another embodiment, the invention features the above method wherein in step e), the Bn protecting groups are removed by hydrogenation.
[00112] In another aspect, the invention features a compound of formula 23:
Figure imgf000036_0001
23
wherein:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive.
[00113] In another embodiment, the invention features a compound of formula 23 and the attendant definitions, wherein ring A is a fused heterocycloalkyl or heteroaryl. In another
Figure imgf000036_0002
. In another embodiment, ring A is .
[00114] In another embodiment, the invention features a compound of formula 23 and the attendant definitions, wherein X is CN. In another embodiment, X is C02Et. [00115] In another embodiment, the invention features a compound of formula 23 and the attendant definitions, wherein m is 0.
[00116] In another embodiment, the invention features a compound of formula 23 and the attendant definitions, wherein RJ is Ci_6 aliphatic. In another embodiment, RJ is -CH2CH3.
[00117] In another aspect, the invention features the compound
Figure imgf000037_0001
[001] In another aspect, the invention features the compound
Figure imgf000037_0002
[00119] Methods of Preparing Compounds of Formulas I, II, III, and IV
[00120] Compounds of formulas I, II, II, and IV may be prepared by the methods of Schemes 1-3.
[00121] Scheme 1. Compounds of formula I and II.
Figure imgf000038_0001
[00122] a = Pd(0) catalyst; b = acid; c = base; d = hydroxide base; e = acid; f = halogenating agent;
[00123] wherein ring A, Rls m, X, RJ, Hal, q, and n are as defined above.
[00124] In Scheme 1, aryl halide IA is reacted with ester IB in the presence of a transition metal catalyst in a suitable solvent (e.g. toluene) to produce ester IC. In esters IB and IC, X can either be CN or C02R. Treatment of IC with an acid in a suitable solvent (e.g.
dimethyl sulfoxide (DMSO)) produces I. Reaction of I with the dihalide IID in the presence of base gives the cycloalkylidene HE. Hydro lization of the cyanide or remaining ester group depending on the identity of X gives the carboxylic acid IIF which is halogenated to yield the acid halide II.
[00125] In one embodiment, IA is commercially available. In one embodiment, ring A is a 5 membered dioxyl ring. In one embodiment, Hal in IA is Br. In one embodiment, the reaction of IA and IIB takes place in toluene in the presence of a Pd(0) caystalyst, e.g. Pd(dba)2. In a further embodiment, the reaction takes place in the presence of an alkyl phosphine, e.g. t- Bu3P and phosphate salt, e.g. Na3P04. In another embodiment, the reaction of IA and IIB takes place at about 70 °C. In another embodiment, RJ is Et.
[00126] In one embodiment, the de-esterification of IC to I is done with an inorganic acid. In a further embodiment, the inorganic acid is HC1. The conversion takes place in an appropriate aprotic solvent (e.g. DMSO) at about 75 °C.
[00127] In one embodiment, I is reacted with NaOH and an alkyl dihalide to yield the cycloalkylidene in a suitable solvent (e.g. MTBE). The process is adaptable to several spirocyclic rings by choosing the appropriate alkyl dihalide. For example, a spirocylic butane ring can be produced by reacting I with, for example, l-bromo-3-chloropropane. It has been found that a mixed bromo and chloro dihalide works best on an economic scale as it is believed that the thermodynamics of the reaction are more favorable.
[00128] In one embodiment, HE is hydrolized to the carboxylic acid IIF in the presence of water and a base (e.g. NaOH) in a suitable solvent (e.g. ethanol). Subseqent treatment with an acid such as HC1 yields IIF. In another embodiment, IIF is worked up by recrystallizing it from toluene.
[00129] In one embodiment, the halogenating agent that converts IIF to II is thionyl chloride. In another embodiment, the thionyl chloride is added to IIF in toluene at about 60 °C. In one embodiment, this step directly proceeds the coupling between II and amine III (see below) and is carried out in the same reaction vessel.
[00130] There are several non-limiting advantages to forming II according to Scheme 1 and the embodiments described above and elsewhere in the application. These advantages are apparent even more so when manufacturing II on an economic scale and include the following. The overall reaction requires only 5 steps, which is less than what's been previously reported (i.e. starting from an aryl carboxylic acid, which is reduced to the methyl alcohol, which is converted to a methyl chloride, which is reacted with NaCN). This synthetic route introduces the CN or ester group (i.e. X) without a separate chlorinating reaction. Using ethanol as the cosolvent in hydrolyzing HE to IIF results in a homogeneous reaction mixture making sampling and monitoring the reaction easier. Recrystallizing IIF from toluene eliminates the need for forming a dicyclohexylamine (DCA) salt as previously reported.
[00131] Scheme 2. Compounds of formula III.
Figure imgf000040_0001
[00132] a = halogenating agent; b = Zn(II) catalyst; c = H2, Pt; d = acid; e = base; f = Pd(II) catalyst;
Θ
[00133] wherein R2, o, Hal, A , and P are defined as above.
[00134] In one embodiment, in IIIA, R2 is F and is meta to the amine group. In another embodiment, IIIA is brominated with N-bromosuccinimide in a suitable solvent (e.g.
ethylacetate) at about 22 °C. [00135] In another embodiment, IIIB is reacted with epoxide IIIC effecting a ring opening reaction with the amine group of IIIB to form HID. In one embodiment, the protecting group, P, in IIIC is benzyl (Bn). In another embodiment epoxide IIIC is chiral. In one embodiment IIIC is (R) IIIC. In another embodiment, IIIC is (S) IIIC. In one embodiment, the ring opening reaction is carried out in a suitable solvent (e.g. toluene) at about 80 °C. In another embodiment, the ring opening reaction takes place in the presence of a Zn(II) catalyst (e.g. Zn(C104)2). In another embodiment, the conversion from IIIB to HID comprises the ring opening reaction with epoxide IIIC, followed by hydrogenation, and then treatment with an acid to form HID. In a further embodiment, hydrogenation is carried out with H2/Pt(S)/C. In a
Θ
further embodiment, the acid is toluene sulfonic acid, such that A is a tosylate anion.
[00136] In another embodiment, alkyne HIE is coupled with HID in a suitable solvent (e.g. acetonitrile) at about 80 °C. In another embodiment, the coupling reaction takes place in the presence of a Pd(II) catalyst, such as Pd(OAc)2. The initial reaction does not result in ring closure, only replacement of the halide on HID. Ring closure is accomplished through reaction with another Pd(II) catalyst, such as (MeCN)2PdCl2 in a suitable solvent (e.g. acetonitrile). In one embodiment, ring closure takes place at about 80 °C. In one embodiment, R3 in alkyne HIE is -C(CH3)2CH2OBn. In one embodiment, the product from the coupling reaction is not isolated but taken up in acetonitrile and reacted with (MeCN)2PdCl2.
[00137] There are several non-limiting advantages to forming compound III according to Scheme 2 and the embodiments described above and elsewhere in the application. These advantages are apparent even more so when manufacturing III on an economic scale and include the following. The overall number of steps have been reduced compared to what was disclosed previously to just 3 steps. Other advantages include the elimination of
chromatography and by-products from protecting groups. [00138] Scheme 3. Compounds of Formula IV.
Figure imgf000042_0001
[00139] a = halogenating agent; b = aprotic solvent;
[00140] wherein ring A, Rls m, n, hal, R2, o, P, and R3 are as defined above.
[00141] An acid-base reaction between II and III in a suitable solvent (e.g.
dichloromethane (DCM)) yields the protected analog of Compound 1. In one embodiment, the acid halide II is prepared from IIF as depicted in Scheme 1 in the same reaction vessel and is not isolated. In another embodiment, the acid-based reaction is carried out in the presence of a base such as triethylamine (TEA). In one embodiment, the amount of TEA is 2 equivalents relative to II. In one embodiment, after a reaction time of about 4 hours at about 0 °C and warming to room temperature overnight, water is added to the mixture and stirred for an additional 30 minutes. The organic phase is separated and IV is isolated by distilling off the reaction solvent. In one embodiment, IV is collected by silica pad filtration. [00142] In another embodiment, compounds of formula IV may be deprotected to form compounds of formula IVa according to Scheme 4.
[00143] Scheme 4. Deprotecting Compounds of Formula IV.
Figure imgf000043_0001
[00144] a = H2/Pd/C;
[00145] wherein ring A, Rls m, n, R2, o, R3, and P are defined as above.
[00146] In one embodiment, hydrogen pressurization is 3 Bars. In another
embodiment, the hydrogenation agitation rate is increased to 800 rpm. In another embodiment, after rapid hydrogen uptake subsides, the hydrogenation vessel is heated to about 50 °C for 2 days. In another embodiment, after the 2 days, more catalyst is added and hydrogenation continues for another 4 days. In another embodiment, IV is dissolved in a suitable solvent (e.g. THF).
[00147] In another embodiment, Compound 1 may be prepared by coupling the acid halide moiety 7 with the amine moiety 8 to form compound 9 followed by deprotection according to Scheme 5.
[00148] Scheme 5. Preparation of Compound 1.
Figure imgf000044_0001
[00149] Wherein Compound 7 is prepared according to Scheme 6.
[00150] Scheme 6.
Figure imgf000045_0001
Touene, H90, 70 °C CN
3 N HC1, DMSO, 75 °C
Figure imgf000045_0002
[00151] Wherein Compound 8 is prepared according to Scheme 7.
[00152] Scheme 7.
Figure imgf000046_0001
[00153] Uses, Formulation and Administration [00154] Pharmaceutically acceptable compositions
[00155] In another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise Compound 1 Form A or amorphous Compound 1 as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
[00156] As described above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating
pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene -polyoxypropylene -block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil;
glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
[00157] Uses of Compounds and Pharmaceutically Acceptable Compositions
[00158] In yet another aspect, the present invention provides a method of treating a condition, disease, or disorder implicated by CFTR. In certain embodiments, the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of CFTR activity, the method comprising administering a composition comprising a Compound 1 described herein to a subject, preferably a mammal, in need thereof.
[00159] A "CFTR-mediated disease" as used herein is a disease selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/T ay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1 , congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia. In another embodiment, the CFTR mediated disease is cystic fibrosis, emphysema, COPD, or osteoporosis. In another embodiment, the CFTR mediated disease is cystic fibrosis.
[00160] In certain embodiments, the present invention provides a method of treating a CFTR-mediated disease in a human comprising the step of administering to said human an effective amount of a composition comprising Compound 1 described herein. [00161] According to the invention an "effective amount" of Compound 1 Form A or amorphous Compound 1 or a pharmaceutically acceptable composition thereof is that amount effective for treating or lessening the severity of any of the diseases recited above.
[00162] Compound 1 or a pharmaceutically acceptable composition thereof may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases recited above.
[00163] In certain embodiments, Compound 1 described herein or a
pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia. The presence of residual CFTR activity at the epithelial surface can be readily detected using methods known in the art, e.g., standard electrophysiological, biochemical, or histochemical techniques. Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary CI" concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be readily detected in patients heterozygous or homozygous for a variety of different mutations, including patients homozygous or heterozygous for the most common mutation, AF508.
[00164] In one embodiment, Compound 1 described herein or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain genotypes exhibiting residual CFTR activity, e.g., class III mutations (impaired regulation or gating), class IV mutations (altered conductance), or class V mutations (reduced synthesis) (Lee R. Choo-Kang, Pamela L., Zeitlin, Type I, II, III, IV, and V cystic fibrosis Tansmembrane Conductance Regulator Defects and Opportunities of Therapy; Current Opinion in Pulmonary Medicine 6:521 - 529, 2000). Other patient genotypes that exhibit residual CFTR activity include patients homozygous for one of these classes or heterozygous with any other class of mutations, including class I mutations, class II mutations, or a mutation that lacks classification.
[00165] In one embodiment, Compound 1 described herein or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain clinical phenotypes, e.g., a moderate to mild clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of epithelia. Such phenotypes include patients exhibiting pancreatic insufficiency or patients diagnosed with idiopathic pancreatitis and congenital bilateral absence of the vas deferens, or mild lung disease.
[00166] The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient" or "subject", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00167] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. [00168] In certain embodiments, the dosage amount of Compound 1 in the dosage unit form is from 100 mg to 1,000 mg. In another embodiment, the dosage amount of
Compound 1 is from 200 mg to 900 mg. In another embodiment, the dosage amount of Compound 1 is from 300 mg to 800 mg. In another embodiment, the dosage amount of Compound 1 is from 400 mg to 700 mg. In another embodiment, the dosage amount of Compound 1 is from 500 mg to 600 mg.
[00169] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[00170] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00171] Compositions for rectal or vaginal administration are preferably
suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00172] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00173] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[00174] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00175] It will also be appreciated that Compound 1 described herein or a pharmaceutically acceptable composition thereof can be employed in combination therapies, that is, Compound 1 can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated".
[00176] In one embodiment, the additional agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of the present invention, or a nutritional agent.
[00177] In one embodiment, the additional therapeutic agent is an antibiotic.
Exemplary antibiotics useful herein include tobramycin, including tobramycin inhaled powder (TIP), azithromycin, aztreonam, including the aerosolized form of aztreonam, amikacin, including liposomal formulations thereof, ciprofloxacin, including formulations thereof suitable for administration by inhalation, levoflaxacin, including aerosolized formulations thereof, and combinations of two antibiotics, e.g., fosfomycin and tobramycin.
[00178] In another embodiment, the additional agent is a mucolyte. Exemplary mucolytes useful herein includes Pulmozyme®.
[00179] In another embodiment, the additional agent is a bronchodialator.
Exemplary bronchodialtors include albuterol, metaprotenerol sulfate, pirbuterol acetate, salmeterol, or tetrabuline sulfate. [00180] In another embodiment, the additional agent is effective in restoring lung airway surface liquid. Such agents improve the movement of salt in and out of cells, allowing mucus in the lung airway to be more hydrated and, therefore, cleared more easily. Exemplary such agents include hypertonic saline, denufosol tetrasodium ([[(3S, 5R)-5-(4-amino-2- oxopyrimidin-l-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5- (2,4-dioxopyrimidin- 1 -yl)-3 , 4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy- hydroxyphosphoryl] hydrogen phosphate), or bronchitol (inhaled formulation of mannitol).
[00181] In another embodiment, the additional agent is an anti-inflammatory agent, i.e., an agent that can reduce the inflammation in the lungs. Exemplary such agents useful herein include ibuprofen, docosahexanoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.
[00182] In another embodiment, the additional agent is a CFTR modulator other than Compound 1, i.e., an agent that has the effect of modulating CFTR activity. Exemplary such agents include ataluren ("PTC 124®"; 3-[5-(2-fluorophenyl)-l,2,4-oxadiazol-3-yl]benzoic acid), sinapultide, lancovutide, depelestat (a human recombinant neutrophil elastase inhibitor), cobiprostone (7-{(2R, 4aR, 5R, 7aR)-2-[(3S)-l,l-difluoro-3-methylpentyl]-2-hydroxy-6- oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid), and N-(5-hydroxy-2,4-ditert-butyl- phenyl)-4-oxo-lH-quinoline-3-carboxamide.
[00183] In another embodiment, the additional agent is a nutritional agent.
Exemplary nutritional agents include pancrelipase (pancreating enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase®, or Creon®, Liprotomase® (formerly Trizytek®), Aquadeks®, or glutathione inhalation. In one embodiment, the additional nutritional agent is pancrelipase.
[00184] In another embodiment, the additional agent is a compound selected from gentamicin, curcumin, cyclophosphamide, 4-phenylbutyrate, miglustat, felodipine, nimodipine, Philoxin B, geniestein, Apigenin, cAMP/cGMP modulators such as rolipram, sildenafil, milrinone, tadalafil, amrinone, isoproterenol, albuterol, and almeterol, deoxyspergualin, HSP 90 inhibitors, HSP 70 inhibitors, proteosome inhibitors such as epoxomicin, lactacystin, etc. [00185] In another embodiment, the additional agent is a compound disclosed in WO 2004028480, WO 2004110352, WO 2005094374, WO 2005120497, or WO 2006101740.
[00186] In another embodiment, the additiona agent is a benzo(c)quinolizinium derivative that exhibits CFTR modulation activity or a benzopyran derivative that exhibits CFTR modulation activity.
[00187] In another embodiment, the addditional agent is a compound disclosed in US7202262, US6992096, US20060148864, US20060148863, US20060035943,
US20050164973, WO2006110483, WO2006044456, WO2006044682, WO2006044505, WO2006044503, WO2006044502, or WO2004091502.
[00188] In another embodiment, the additional agent is a compound disclosed in WO2004080972, WO2004111014, WO2005035514, WO2005049018, WO2006099256, WO2006127588, or WO2007044560.
[00189] These combinations are useful for treating the diseases described herein including cystic fibrosis. These combinations are also useful in the kits described herein.
[00190] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[00191] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLES
[00192] Methods & Materials
[00193] Vitride® (sodium bis(2-methoxyethoxy)aluminum hydride [or
NaAlH2(OCH2CH2OCFl3)2], 65 wgt% solution in toluene) was purchased from Aldrich Chemicals. 3-Fluoro-4-nitroaniline was purchased from Capot Chemicals. 5-Bromo-2,2- difluoro- 1 ,3-benzodioxole was purchased from Alfa Aesar. 2,2-Difluoro- 1 ,3-benzodioxole-5- carboxylic acid was purchased from Saltigo (an affiliate of the Lanxess Corporation).
[00194] Anywhere in the present application where a name of a compound may not correctly describe the structure of the compound, the structure supersedes the name and governs.
[00195] Synthesis of Compound 1 [00196] Acid Moiety
[00197] Synthesis of (2,2-difluoro-l,3-benzodioxol-5-yl)-l-ethylacetate-acetonitrile
Figure imgf000056_0001
[00198] A reactor was purged with nitrogen and charged with 900 mL of toluene. The solvent was degassed via nitrogen sparge for no less than 16 h. To the reactor was then charged Na3P04 (155.7 g, 949.5 mmol), followed by bis(dibenzylideneacetone) palladium (0) (7.28 g, 12.66 mmol). A 10% w/w solution of tert-butylphosphine in hexanes (51.23 g, 25.32 mmol) was charged over 10 min at 23 °C from a nitrogen purged addition funnel. The mixture was allowed to stir for 50 min, at which time 5-bromo-2,2-difluoro-l,3-benzodioxole (75 g, 316.5 mmol) was added over 1 min. After stirring for an additional 50 min, the mixture was charged with ethyl cyanoacetate (71.6 g, 633.0 mmol) over 5 min followed by water (4.5 mL) in one portion. The mixture was heated to 70 °C over 40 min and analyzed by HPLC every 1 - 2 h for the percent conversion of the reactant to the product. After complete conversion was observed (typically 100% conversion after 5 - 8 h), the mixture was cooled to 20 - 25 °C and filtered through a celite pad. The celite pad was rinsed with toluene (2 X 450 mL) and the combined organics were concentrated to 300 mL under vacuum at 60 - 65 °C. The concentrate was charged with 225mL DMSO and concentrated under vacuum at 70 - 80 °C until active distillation of the solvent ceased. The solution was cooled to 20 - 25 °C and diluted to 900 mL with DMSO in preparation for Step 2. 1H NMR (500 MHz, CDC13) δ 7.16 - 7.10 (m, 2H), 7.03 (d, J= 8.2 Hz, 1H), 4.63 (s, lH), 4.19 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H). [00199] Synthesis of (2,2-difluoro- 1 ,3-benzodioxol-5-yl)-acetonitrile.
Figure imgf000057_0001
[00200] The DMSO solution of (2,2-difluoro- 1 ,3-benzodioxol-5-yl)- 1 -ethylacetate- acetonitrile from above was charged with 3 N HC1 (617.3 mL, 1.85 mol) over 20 min while maintaining an internal temperature < 40 °C. The mixture was then heated to 75°C over 1 h and analyzed by HPLC every 1 - 2 h for % conversion. When a conversion of > 99% was observed (typically after 5 - 6 h), the reaction was cooled to 20 - 25 °C and extracted with MTBE (2 X 525 mL), with sufficient time to allow for complete phase separation during the extractions. The combined organic extracts were washed with 5% NaCl (2 X 375 mL). The solution was then transferred to equipment appropriate for a 1.5 - 2.5 Torr vacuum distillation that was equipped with a cooled receiver flask. The solution was concentrated under vacuum at < 60°C to remove the solvents. (2,2-Difluoro-l,3-benzodioxol-5-yl)-acetonitrile was then distilled from the resulting oil at 125 - 130 °C (oven temperature) and 1.5 - 2.0 Torr. (2,2- Difluoro-l,3-benzodioxol-5-yl)-acetonitrile was isolated as a clear oil in 66% yield from 5- bromo-2,2-difluoro-l,3-benzodioxole (2 steps) and with an HPLC purity of 91.5% AUC (corresponds to a w/w assay of 95%). 1H NMR (500 MHz, DMSO) δ 7.44 (br s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.22 (dd, J= 8.2, 1.8 Hz, 1H), 4.07 (s, 2H).
[00201 ] Synthesis of (2,2-difluoro- 1 ,3-benzodioxol-5-yl)-cyclopropanecarbonitrile.
Figure imgf000057_0002
MTBE
[00202] A stock solution of 50% w/w NaOH was degassed via nitrogen sparge for no less than 16 h. An appropriate amount of MTBE was similarly degassed for several hours. To a reactor purged with nitrogen was charged degassed MTBE (143 mL) followed by (2,2- difluoro- l,3-benzodioxol-5-yl)-acetonitrile (40.95 g, 207.7 mmol) and tetrabutylammonium bromide (2.25 g, 10.38 mmol). The volume of the mixture was noted and the mixture was degassed via nitrogen sparge for 30 min. Enough degassed MTBE is charged to return the mixture to the original volume prior to degassing. To the stirring mixture at 23.0 °C was charged degassed 50% w/w NaOH (143 mL) over 10 min followed by l-bromo-2-chloroethane (44.7 g, 311.6 mmol) over 30 min. The reaction was analyzed by HPLC in 1 h intervals for % conversion. Before sampling, stirring was stopped and the phases allowed to separate. The top organic phase was sampled for analysis. When a % conversion > 99 % was observed (typically after 2.5 - 3 h), the reaction mixture was cooled to 10 °C and was charged with water (461 mL) at such a rate as to maintain a temperature < 25 °C. The temperature was adjusted to 20 - 25 °C and the phases separated. Note: sufficient time should be allowed for complete phase separation. The aqueous phase was extracted with MTBE (123 mL), and the combined organic phase was washed with 1 N HC1 (163mL) and 5% NaCl (163 mL). The solution of (2,2- difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarbonitrile in MTBE was concentrated to 164 mL under vacuum at 40 - 50 °C. The solution was charged with ethanol (256 mL) and again concentrated to 164 mL under vacuum at 50 - 60 °C. Ethanol (256 mL) was charged and the mixture concentrated to 164 mL under vacuum at 50 - 60 °C. The resulting mixture was cooled to 20 - 25 °C and diluted with ethanol to 266 mL in preparation for the next step. 1H NMR (500 MHz, DMSO) 5 7.43 (d, J= 8.4 Hz, 1H), 7.40 (d, J= 1.9 Hz, 1H), 7.30 (dd, J= 8.4, 1.9 Hz, 1H), 1.75 (m, 2H), 1.53 (m, 2H).
[00203] Synthesis of l-(2,2-difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarboxylic acid.
Figure imgf000058_0001
[00204] The solution of (2,2-difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarbonitrile in ethanol from the previous step was charged with 6 N NaOH (277 mL) over 20 min and heated to an internal temperature of 77 - 78 °C over 45 min. The reaction progress was monitored by HPLC after 16 h. Note: the consumption of both (2,2-difluoro-l,3-benzodioxol- 5-yl)-cyclopropanecarbonitrile and the primary amide resulting from partial hydrolysis of (2,2- difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarbonitrile were monitored. When a % conversion > 99 % was observed (typically 100% conversion after 16 h), the reaction mixture was cooled to 25 °C and charged with ethanol (41 mL) and DCM (164 mL). The solution was cooled to 10 °C and charged with 6 N HC1 (290 mL) at such a rate as to maintain a temperature < 25 °C. After warming to 20 - 25 °C, the phases were allowed to separate. The bottom organic phase was collected and the top aqueous phase was back extracted with DCM (164 mL). Note: the aqueous phase was somewhat cloudy before and after the extraction due to a high concentration of inorganic salts. The organics were combined and concentrated under vacuum to 164 mL. Toluene (328 mL) was charged and the mixture condensed to 164 mL at 70 - 75 °C. The mixture was cooled to 45 °C, charged with MTBE (364 mL) and stirred at 60 °C for 20 min. The solution was cooled to 25 °C and polish filtered to remove residual inorganic salts. MTBE (123 mL) was used to rinse the reactor and the collected solids. The combined organics were transferred to a clean reactor in preparation for the next step.
[00205] Isolation of l-(2,2-difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarboxylic acid.
Figure imgf000059_0001
[00206] The solution of 1 -(2,2-difluoro- 1 ,3-benzodioxol-5-yl)-cyclopropanecarboxylic acid from the previous step is concentrated under vacuum to 164 mL, charged with toluene (328 mL) and concentrated to 164 mL at 70 - 75 °C. The mixture was then heated to 100 - 105 °C to give a homogeneous solution. After stirring at that temperature for 30 min, the solution was cooled to 5 °C over 2 hours and maintained at 5 °C for 3 hours. The mixture was then filtered and the reactor and collected solid washed with cold 1 : 1 toluene/n-heptane (2 X 123 mL). The material was dried under vacuum at 55 °C for 17 hours to provide 1 -(2,2-difluoro- 1,3- benzodioxol-5-yl)-cyclopropanecarboxylic acid as an off- white crystalline solid. 1 -(2,2- difluoro- 1,3 -benzodioxol-5-yl)-cyclopropanecarboxylic acid was isolated in 79% yield from (2,2-difluoro-l,3-benzodioxol-5-yl)-acetonitrile (3 steps including isolation) and with an HPLC purity of 99.0% AUC. ESI-MS m/z calc. 242.04, found 241.58 (M+l)+; 1H NMR (500 MHz, DMSO) δ 12.40 (s, 1H), 7.40 (d, J= 1.6 Hz, 1H), 7.30 (d, J= 8.3 Hz, 1H), 7.17 (dd, J= 8.3, 1.7 Hz, 1H), 1.46 (m, 2H), 1.17 (m, 2H).
[00207] Alternative Synthesis of the Acid Moiety [00208] Synthesis of (2,2-difluoro-l,3-benzodioxol-5-yl)-methanol.
1. Vitride (2 equiv)
Figure imgf000060_0001
86-92% y e
[00209] Commercially available 2,2-difluoro-l,3-benzodioxole-5-carboxylic acid (1.0 eq) is slurried in toluene (10 vol). Vitride® (2 eq) is added via addition funnel at a rate to maintain the temperature at 15-25 °C. At the end of addition the temperature is increased to 40 °C for 2 h then 10%> (w/w) aq. NaOH (4.0 eq) is carefully added via addition funnel maintaining the temperature at 40-50 °C. After stirring for an additional 30 minutes, the layers are allowed to separate at 40 °C. The organic phase is cooled to 20 °C then washed with water (2 x 1.5 vol), dried (Na2S04), filtered, and concentrated to afford crude (2,2-difluoro-l,3- benzodioxol-5-yl)-methanol that is used directly in the next step.
[00210] Synthesis of 5-chloromethyl-2,2-difluoro-l,3-benzodioxole.
1. SOCl2 (1.5 equiv)
DMAP (0.01 equiv)
2. water (4 vol)
Figure imgf000060_0002
[00211] (2,2-difluoro-l,3-benzodioxol-5-yl)-methanol (1.0 eq) is dissolved in MTBE (5 vol). A catalytic amount of DMAP (1 mol %) is added and SOCl2 (1.2 eq) is added via addition funnel. The SOCl2 is added at a rate to maintain the temperature in the reactor at 15-25 °C. The temperature is increased to 30 °C for 1 hour then cooled to 20 °C then water (4 vol) is added via addition funnel maintaining the temperature at less than 30 °C. After stirring for an additional 30 minutes, the layers are allowed to separate. The organic layer is stirred and 10% (w/v) aq. NaOH (4.4 vol) is added. After stirring for 15 to 20 minutes, the layers are allowed to separate. The organic phase is then dried (Na2S04), filtered, and concentrated to afford crude 5-chloromethyl-2,2-difluoro-l,3-benzodioxole that is used directly in the next step. [00212] Synthesis of (2,2-difluoro-l,3-benzodioxol-5-yl)-acetonitrile.
Figure imgf000061_0001
[00213] A solution of 5-chloromethyl-2,2-difluoro-l,3-benzodioxole (1 eq) in DMSO (1.25 vol) is added to a slurry of NaCN (1.4 eq) in DMSO (3 vol) maintaining the temperature between 30-40 °C. The mixture is stirred for 1 hour then water (6 vol) is added followed by MTBE (4 vol). After stirring for 30 min, the layers are separated. The aqueous layer is extracted with MTBE (1.8 vol). The combined organic layers are washed with water (1.8 vol), dried (Na2S04), filtered, and concentrated to afford crude (2,2-difluoro-l,3-benzodioxol-5-yl)- acetonitrile (95%) that is used directly in the next step.
[00214] The remaining steps are the same as described above for the synthesis of the acid moiety.
[00215] Amine Moiety
[00216] Synthesis of 2-bromo-5-fluoro-4-nitroaniline.
Figure imgf000061_0002
A flask was charged with 3-fluoro-4-nitroaniline (1.0 equiv) followed by ethyl acetate (10 vol) and stirred to dissolve all solids. N-Bromosuccinimide (1.0 equiv) was added as a portion- wise as to maintain internal temperature of 22 °C. At the end of the reaction, the reaction mixture was concentrated in vacuo on a rotavap. The residue was slurried in distilled water (5 vol) to dissolve and remove succinimide. (The succinimide can also be removed by water workup procedure.) The water was decanted and the solid was slurried in 2-propanol (5 vol) overnight. The resulting slurry was filtered and the wetcake was washed with 2- propanol, dried in vacuum oven at 50 °C overnight with N2 bleed until constant weight was achieved. A yellowish tan solid was isolated (50%> yield, 97.5% AUC). Other impurities were a bromo- regioisomer (1.4% AUC) and a di-bromo adduct (1.1% AUC). 1H NMR (500 MHz, DMSO) δ 8.19 (1 H, d, J= 8.1 Hz), 7.06 (br. s, 2 H), 6.64 (d, 1 H, J= 14.3 Hz).
[00217] Synthesis of / oluenesulfonic acid salt of (R)-l-((4-amino-2-bromo-5- fluorophenyl)amino)-3-(benzyloxy)propan-2-ol.
1) >^OBn
cat. Zn(C104)2-2H20 Θ
Figure imgf000062_0001
[00218] A thoroughly dried flask under N2 was charged with the following: Activated powdered 4A molecular sieves (50 wt% based on 2-bromo-5-fluoro-4-nitroaniline), 2-Bromo-5- fluoro-4-nitroaniline (1.0 equiv), zinc perchlorate dihydrate (20 mol%), and toluene (8 vol). The mixture was stirred at room temperature for NMT 30 min. Lastly, (R)-benzyl glycidyl ether (2.0 equiv) in toluene (2 vol) was added in a steady stream. The reaction was heated to 80 °C (internal temperature) and stirred for approximately 7 hours or until 2-Bromo-5-fluoro-4- nitroaniline was <5%AUC.
[00219] The reaction was cooled to room temperature and Celite (50 wt%) was added, followed by ethyl acetate (10 vol). The resulting mixture was filtered to remove Celite and sieves and washed with ethyl acetate (2 vol). The filtrate was washed with ammonium chloride solution (4 vol, 20% w/v). The organic layer was washed with sodium bicarbonate solution (4 vol x 2.5% w/v). The organic layer was concentrated in vacuo on a rotovap. The resulting slurry was dissolved in isopropyl acetate (10 vol) and this solution was transferred to a Buchi hydrogenator.
[00220] The hydrogenator was charged with 5wt% Pt(S)/C (1.5 mol%>) and the mixture was stirred under N2 at 30 °C (internal temperature). The reaction was flushed with N2 followed by hydrogen. The hydrogenator pressure was adjusted to 1 Bar of hydrogen and the mixture was stirred rapidly (>1200 rpm). At the end of the reaction, the catalyst was filtered through a pad of Celite and washed with dichloromethane (10 vol). The filtrate was concentrated in vacuo. Any remaining isopropyl acetate was chased with dichloromethane (2 vol) and concentrated on a rotavap to dryness.
[00221] The resulting residue was dissolved in dichloromethane (10 vol), p- Toluenesulfonic acid monohydrate (1.2 equiv) was added and stirred overnight. The product was filtered and washed with dichloromethane (2 vol) and suction dried. The wetcake was transferred to drying trays and into a vacuum oven and dried at 45 °C with N2 bleed until constant weight was achieved. /^-Toluenesulfonic acid salt of (i?)-l-((4-amino-2-bromo-5- fluorophenyl)amino)-3-(benzyloxy)propan-2-ol was isolated as an off-white solid.
[00222] Chiral purity was determined to be >97%ee.
[00223] Synthesis of (3-Chloro-3-methylbut-l-ynyl)trimethylsilane.
Figure imgf000063_0001
[00224] Propargyl alcohol (1.0 equiv) was charged to a vessel. Aqueous hydrochloric acid (37%, 3.75 vol) was added and stirring begun. During dissolution of the solid alcohol, a modest endotherm (5-6 °C) is observed. The resulting mixture was stirred overnight (16 h), slowly becoming dark red. A 30 L jacketed vessel is charged with water (5 vol) which is then cooled to 10 °C. The reaction mixture is transferred slowly into the water by vacuum, maintaining the internal temperature of the mixture below 25 °C. Hexanes (3 vol) is added and the resulting mixture is stirred for 0.5 h. The phases were settled and the aqueous phase (pH < 1) was drained off and discarded. The organic phase was concentrated in vacuo using a rotary evaporator, furnishing the product as red oil.
[00225] Synthesis of (4-(Benzyloxy)-3,3-dimethylbut-l-ynyl)trimethylsilane.
Figure imgf000063_0002
[00226] Method A [00227] All equivalent and volume descriptors in this part are based on a 25 Og reaction. Magnesium turnings (69.5 g, 2.86 mol, 2.0 equiv) were charged to a 3 L 4-neck reactor and stirred with a magnetic stirrer under nitrogen for 0.5 h. The reactor was immersed in an ice- water bath. A solution of the propargyl chloride (250 g, 1.43 mol, 1.0 equiv) in THF (1.8 L, 7.2 vol) was added slowly to the reactor, with stirring, until an initial exotherm (~10 °C) was observed. The Grignard reagent formation was confirmed by IPC using 1H-NMR spectroscopy. Once the exotherm subsided, the remainder of the solution was added slowly, maintaining the batch temperature <15 °C. The addition required ~3.5 h. The resulting dark green mixture was decanted into a 2 L capped bottle.
[00228] All equivalent and volume descriptors in this part are based on a 500g reaction. A 22 L reactor was charged with a solution of benzyl chloromethyl ether (95%, 375 g, 2.31 mol, 0.8 equiv) in THF (1.5 L, 3 vol). The reactor was cooled in an ice-water bath. Two Grignard reagent batches prepared as described above were combined and then added slowly to the benzyl chloromethyl ether solution via an addition funnel, maintaining the batch
temperature below 25 °C. The addition required 1.5 h. The reaction mixture was stirred overnight (16 h).
[00229] All equivalent and volume descriptors in this part are based on a 1 kg reaction. A solution of 15% ammonium chloride was prepared in a 30 L jacketed reactor (1.5 kg in 8.5 kg of water, 10 vol). The solution was cooled to 5 °C. Two Grignard reaction mixtures prepared as described above were combined and then transferred into the ammonium chloride solution via a header vessel. An exotherm was observed in this quench, which was carried out at a rate such as to keep the internal temperature below 25 °C. Once the transfer was complete, the vessel jacket temperature was set to 25 °C. Hexanes (8 L, 8 vol) was added and the mixture was stirred for 0.5 h. After settling the phases, the aqueous phase (pH 9) was drained off and discarded. The remaining organic phase was washed with water (2 L, 2 vol). The organic phase was concentrated in vacuo using a 22 L rotary evaporator, providing the crude product as an orange oil.
[00230] Method B [00231] Magnesium turnings (106 g, 4.35 mol, 1.0 eq) were charged to a 22 L reactor and then suspended in THF (760 mL, 1 vol). The vessel was cooled in an ice-water bath such that the batch temperature reached 2 °C. A solution of the propargyl chloride (760 g, 4.35 mol, 1.0 equiv) in THF (4.5 L, 6 vol) was added slowly to the reactor. After 100 mL was added, the addition was stopped and the mixture stirred until a 13 °C exotherm was observed, indicating the Grignard reagent initiation. Once the exotherm subsided, another 500 mL of the propargyl chloride solution was added slowly, maintaining the batch temperature <20 °C. The Grignard reagent formation was confirmed by IPC using 1H-NMR spectroscopy. The remainder of the propargyl chloride solution was added slowly, maintaining the batch temperature <20 °C. The addition required ~1.5 h. The resulting dark green solution was stirred for 0.5 h. The Grignard reagent formation was confirmed by IPC using 1H-NMR spectroscopy. Neat benzyl chloromethyl ether was charged to the reactor addition funnel and then added dropwise into the reactor, maintaining the batch temperature below 25 °C. The addition required 1.0 h. The reaction mixture was stirred overnight. The aqueous work-up and concentration was carried out using the same procedure and relative amounts of materials as in Method A to give the product as an orange oil.
[00232] Syntheisis of 4-Benzyloxy-3,3-dimethylbut-l-yne.
Figure imgf000065_0001
2 steps
[00233] A 30 L jacketed reactor was charged with methanol (6 vol) which was then cooled to 5 °C. Potassium hydroxide (85%, 1.3 equiv) was added to the reactor. A 15-20 °C exotherm was observed as the potassium hydroxide dissolved. The jacket temperature was set to 25 °C. A solution of 4-benzyloxy-3,3-dimethyl-l-trimethylsilylbut-l-yne (1.0 equiv) in methanol (2 vol) was added and the resulting mixture was stirred until reaction completion, as monitored by HPLC. Typical reaction time at 25 °C is 3-4 h. The reaction mixture is diluted with water (8 vol) and then stirred for 0.5 h. Hexanes (6 vol) was added and the resulting mixture was stirred for 0.5 h. The phases were allowed to settle and then the aqueous phase (pH 10-11) was drained off and discarded. The organic phase was washed with a solution of KOH (85%, 0.4 equiv) in water (8 vol) followed by water (8 vol). The organic phase was then concentrated down using a rotary evaporator, yielding the title material as a yellow-orange oil. Typical purity of this material is in the 80% range with primarily a single impurity present. 1H NMR (400 MHz, C6D6) δ 7.28 (d, 2 H, J= 7.4 Hz), 7.18 (t, 2 H, J= 7.2 Hz), 7.10 (d, 1H, J = 7.2 Hz), 4.35 (s, 2 H), 3.24 (s, 2 H), 1.91 (s, 1 H), 1.25 (s, 6 H).
[00234] Synthesis of V-benzylglycolated-5-amino-2-(2-benzyloxy-l,l- dimethylethyl)-6-fluoroindole.
[00235] Method A
[00236] Synthesis of (R)-l-((4-amino-2-(4-(benzyloxy)-3,3-dimethylbut-l-yn-l-yl)- 5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol.
Figure imgf000066_0001
[00237] /?-Toluenesulfonic acid salt of (i?)-l-((4-amino-2-bromo-5- fluorophenyl)amino)-3-(benzyloxy)propan-2-ol was freebased by stirring the solid in dichloromethane (5 vol) and saturated NaHC03 solution (5 vol) until clear organic layer was achieved. The resulting layers were separated and the organic layer was washed with saturated NaHC03 solution (5 vol) followed by brine and concentrated in vacuo to obtain (i?)-l-((4- amino-2-bromo-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol free base as an oil.
[00238] Palladium acetate (0.01 eq), dppb (0.015 eq), Cul (0.015 eq) and potassium carbonate (3 eq) are suspended in acetonitrile (1.2 vol). After stirring for 15 minutes, a solution of 4-benzyloxy-3,3-dimethylbut-l-yne (1.1 eq) in acetonitrile (0.2 vol) is added. The mixture is sparged with nitrogen gas for 1 h and then a solution of (i?)-l-((4-amino-2-bromo-5- fluorophenyl)amino)-3-(benzyloxy)propan-2-ol free base (1 eq) in acetonitrile (4.1 vol) is added. The mixture is sparged with nitrogen gas for another hour and then is heated to 80 °C. Reaction progress is monitored by HPLC and the reaction is usually complete within 3-5 h. The mixture is cooled to room temperature and then filtered through Celite. The cake is washed with acetonitrile (4 vol). The combined filtrates are azeotroped to dryness and then the mixture is polish filtered into the next reactor. The acetonitrile solution of (i?)-l-((4-amino-2-(4- (benzyloxy)-3 ,3-dimethylbut- 1 -yn- 1 -yl)-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol thus obtained is used directly in the next procedure (cyclization) without further manipulation.
[00239] Synthesis of V-benzylglycolated-5-amino-2-(2-benzyloxy-l,l- dimethylethyl)-6-fluoroindole.
Figure imgf000067_0001
[00240] 55-acetonitriledichloropalladium (0.1 eq) and Cul (0.1 eq) are charged to the reactor and then suspended in a solution of (i?)-l-((4-amino-2-(4-(benzyloxy)-3,3-dimethylbut- l-yn-l-yl)-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol obtained above (1 eq) in acetonitrile (9.5 vol total). The mixture is sparged with nitrogen gas for 1 h and then is heated to 80 °C. The reaction progress is monitored by HPLC and the reaction is typically complete within 1-3 h. The mixture is filtered through Celite and the cake is washed with acetonitrile. A solvent swap into ethyl acetate (7.5 vol) is performed. The ethyl acetate solution is washed with aqueous NH3-NH4CI solution (2 x 2.5 vol) followed by 10% brine (2.5 vol). The ethyl acetate solution is then stirred with silica gel (1.8 wt eq) and Si-TMT (0.1 wt eq) for 6 h. After filtration, the resulting solution is concentrated down. The residual oil is dissolved in DCM / heptane (4 vol) and then purified by column chromatography. The oil thus obtained is then crystallized from 25% EtOAc / heptane (4 vol). Crystalline (i?)-l-(5-amino-2-(l-(benzyloxy)-2- methylpropan-2-yl)-6-fluoro-lH-indol-l-yl)-3-(benzyloxy)propan-2-ol is typically obtained in 27-38% yield. 1H NMR (400 MHz, DMSO) δ 7.38-7.34 (m, 4 H), 7.32-7.23 (m, 6 H), 7.21 (d, 1 H, J= 12.8 Hz), 6.77 (d, 1H, J= 9.0 Hz), 6.06 (s, 1 H), 5.13 (d, 1H, J= 4.9 Hz), 4.54 (s, 2 H), 4.46 (br. s, 2 H), 4.45 (s, 2 H), 4.33 (d, 1 H, J= 12.4 Hz), 4.09-4.04 (m, 2 H), 3.63 (d, 1H, J = 9.2 Hz), 3.56 (d, 1H, J= 9.2 Hz), 3.49 (dd, 1H, J= 9.8, 4.4 Hz), 3.43 (dd, 1H, J 1.40 (s, 6 H).
[00241 ] Synthesis of V-benzylglycolated-5-amino-2-(2-benzyloxy-l , 1
dimethylethyl)-6-fluoroindole.
[00242] Method B
Figure imgf000068_0001
2 (MeCN)2PdCl2
MeCN, 80 °C
3 Silica gel filtration
[00243] Palladium acetate (33 g, 0.04 eq), dppb (94 g, 0.06 eq), and potassium carbonate (1.5 kg, 3.0 eq) are charged to a reactor. The free based oil benzylglocolated 4- ammonium-2-bromo-5-flouroaniline (1.5 kg, 1.0 eq) was dissolved in acetonitrile (8.2 L, 4.1 vol) and then added to the reactor. The mixture was sparged with nitrogen gas for NLT 1 h. A solution of 4-benzyloxy-3,3-dimethylbut-l-yne (70%, 1.1 kg, 1.05 eq) in acetonitrile was added to the mixture which was then sparged with nitrogen gas for NLT 1 h. The mixture was heated to 80 °C and then stirred overnight. IPC by HPLC is carried out and the reaction is determined to be complete after 16 h. The mixture was cooled to ambient temperature and then filtered through a pad of Celite (228 g). The reactor and Celite pad were washed with acetonitrile (2 x 2 L, 2 vol). The combined phases are concentrated on a 22 L rotary evaporator until 8 L of solvent have been collected, leaving the crude product in 7 L (3.5 vol) of acetonitrile.
[00244] 55-acetonitriledichloropalladium (144 g, 0.15 eq) was charged to the reactor. The crude solution was transferred back into the reactor and the roto-vap bulb was washed with acetonitrile (4 L, 2 vol). The combined solutions were sparged with nitrogen gas for NLT 1 h. The reaction mixture was heated to 80 °C for NLT 16 h. In process control by HPLC shows complete consumption of starting material. The reaction mixture was filtered through Celite (300 g). The reactor and filter cake were washed with acetonitrile (3 L, 1.5 vol). The combined filtrates were concentrated to an oil by rotary evaporation. The oil was dissolved in ethyl acetate (8.8 L, 4.4 vol). The solution was washed with 20% ammonium chloride (5 L, 2.5 vol) followed by 5% brine (5 L, 2.5 vol). Silica gel (3.5 kg, 1.8 wt. eq.) of silica gel was added to the organic phase, which was stirred overnight. Deloxan THP II metal scavenger (358 g) and heptane (17.6 L) were added and the resulting mixture was stirred for NLT 3 h. The mixture was filtered through a sintered glass funnel. The filter cake was washed with 30% ethyl acetate in heptane (25 L). The combined filtrates were concentrated under reduced pressure to give N- benzylglycolated-5-amino-2-(2-benzyloxy-l,l-dimethylethyl)-6-fluoroindole as a brown paste (1.4 kg).
[00245] Synthesis of Compound 1
[00246] Synthesis of benzyl protected Compound 1.
Figure imgf000069_0001
[00247] l-(2,2-Difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarboxylic acid (1.3 equiv) was slurried in toluene (2.5 vol, based on l-(2,2-difluoro-l,3-benzodioxol-5-yl)- cyclopropanecarboxylic acid). Thionyl chloride (SOCl2, 1.7 equiv) was added via addition funnel. and the mixture was heated to 60 °C. The resulting mixture was stirred for 2 h. The toluene and the excess SOC12 were distilled off using rotavop. Additional toluene (2.5 vol, based on l-(2,2-difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarboxylic acid) was added and the mixture was distilled down to 1 vol of toluene. A solution of (i?)-l-(5-amino-2-(l- (benzyloxy)-2-methylpropan-2-y l)-6-fiuoro- 1 H-indol- 1 -yl)-3 -(benzyloxy)propan-2-ol ( 1 eq) and triethylamine (3 eq) in DCM (4 vol) is cooled to 0 °C. The acid chloride solution in toluene (1 vol) is added while maintaining the batch temperature below 10 °C. The reaction progress is monitored by HPLC, and the reaction is usually complete within minutes. After warming to 25 °C, the reaction mixture is washed with 5% NaHC03 (3.5 vol), 1 M NaOH (3.5 vol) and 1 M HCl (5 vol). A solvent swap to into methanol (2 vol) is performed and the resulting solution of (i?)-N-(l-(3-(benzyloxy)-2-hydroxypropyl)-2-(l-(benzyloxy)-2-methylpropan-2-yl)-6-fluoro- lH-indol-5-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5-yl)cyclopropanecarboxamide in methanol is used without further manipulation in the next step (hydrogenolysis).
[00248] Synthesis of Compound 1.
Figure imgf000070_0001
[00249] 5% palladium on charcoal (-50% wet, 0.01 eq) is charged to an appropriate hydrogenation vessel. The (i?)-N-(l-(3-(benzyloxy)-2-hydroxypropyl)-2-(l-(benzyloxy)-2- methylpropan-2-yl)-6-fluoro-lH-indol-5-yl)-l-(2,2-difluorobenzo[(i][l,3]dioxol-5- yl)cyclopropanecarboxamide solution in methanol (2 vol) obtained above is added carefully, followed by a 3 M solution of HCl in methanol. The vessel is purged with nitrogen gas and then with hydrogen gas. The mixture is stirred vigorously until the reaction is complete, as determined by HPLC analysis. Typical reaction time is 3-5 h. The reaction mixture is filtered through Celite and the cake is washed with methanol (2 vol). A solvent swap into isopropanol (3 vol) is performed. Crude VX-661 is crystallized from 75% IPA-heptane (4 vol, ie. 1 vol heptane added to the 3 vol of IP A) and the resulting crystals are matured in 50% IPA-heptane (ie. 2 vol of heptane added to the mixture). Typical yields of compound 4 from the two-step acylation / hydrogenolysis procedure range from 68% to 84%. Compound 4 can be
recrystallized from IPA-heptane following the same procedure just described.
[00250] Compound 1 may also be prepared by one of several synthetic routes disclosed in US published patent application US20090131492, incorporated herein by reference.
[00251] Table 10 below recites analytical data for Compound 1.
Table 10.
Cmpd. LC.'MS LC 'RT mm
Figure imgf000071_0001
[00252] ASSAYS
[00253] Assays for Detecting and Measuring AF508-CFTR Correction Properties of Compounds
[00254] Membrane potential optical methods for assaying AF508-CFTR modulation properties of compounds
[00255] The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00256] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission were monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates. [00257] I. Identification of Correction Compounds
[00258] To identify small molecules that correct the trafficking defect associated with AF508-CFTR; a single-addition HTS assay format was developed. The cells were incubated in serum-free medium for 16 hrs at 37 °C in the presence or absence (negative control) of test compound. As a positive control, cells plated in 384-well plates were incubated for 16 hrs at 27 °C to "temperature-correct" AF508-CFTR. The cells were subsequently rinsed 3X with Krebs Ringers solution and loaded with the voltage-sensitive dyes. To activate AF508-CFTR, 10 μΜ forskolin and the CFTR potentiator, genistein (20 μΜ), were added along with Cl'-free medium to each well. The addition of Cl'-free medium promoted CI' efflux in response to AF508-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET- based voltage-sensor dyes.
[00259] 2. Identification of Potentiator Compounds
[00260] To identify potentiators of AF508-CFTR, a double-addition HTS assay format was developed. During the first addition, a Cl'-free medium with or without test compound was added to each well. After 22 sec, a second addition of Cl'-free medium containing 2 - 10 μΜ forskolin was added to activate AF508-CFTR. The extracellular CI' concentration following both additions was 28 mM, which promoted CI' efflux in response to AF508-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET-based voltage-sensor dvesJ. Solutions
Bath Solution #1 : (in mM) NaCl 160, KC1 4.5, CaCl2 2, MgCl2 1,
HEPES 10, pH 7.4 with NaOH.
Chloride-free bath solution Chloride salts in Bath Solution #1 are substituted with gluconate salts.
CC2-DMPE: Prepared as a 10 mM stock solution in
DMSO and stored at -20°C. DiSBAC2(3): Prepared as a 10 mM stock in DMSO and stored at -20°C.
[00262] 4. Cell Culture
[00263] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for optical measurements of membrane potential. The cells are maintained at 37 °C in 5% C02 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 °C before culturing at 27 °C for 24 hrs for the potentiator assay. For the correction assays, the cells are cultured at 27 °C or 37 °C with and without compounds for 16 - 24 hours.
[00264] Electrophysiological Assays for assaying AF508-CFTR modulation properties of compounds
[00265] 1. Ussing Chamber Assay
[00266] Using chamber experiments were performed on polarized epithelial cells expressing AF508-CFTR to further characterize the AF508-CFTR modulators identified in the optical assays. pRjAF508-CFTR epithelial cells grown on Costar Snapwell cell culture inserts were mounted in an Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of Iowa, IA, and, Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2-mV pulse. Under these conditions, the FRT epithelia demonstrated resistances of 4 ΚΩ/ cm2 or more. The solutions were maintained at 27 °C and bubbled with air. The electrode offset potential and fluid resistance were corrected using a cell-free insert. Under these conditions, the current reflects the flow of CI" through AF508-CFTR expressed in the apical membrane. The Isc was digitally acquired using an MP100A-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
[00267] 2. Identification of Correction Compounds [00268] Typical protocol utilized a basolateral to apical membrane CI" concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large CI" concentration gradient across the epithelium. All experiments were performed with intact monolayers. To fully activate AF508-CFTR, forskolin (10 μΜ) and the PDE inhibitor, IBMX (100 μΜ), were applied followed by the addition of the CFTR potentiator, genistein (50 μΜ).
[00269] As observed in other cell types, incubation at low temperatures of FRT cells stably expressing AF508-CFTR increases the functional density of CFTR in the plasma membrane. To determine the activity of correction compounds, the cells were incubated with 10 μΜ of the test compound for 24 hours at 37°C and were subsequently washed 3X prior to recording. The cAMP- and genistein-mediated Isc in compound-treated cells was normalized to the 27°C and 37°C controls and expressed as percentage activity. Preincubation of the cells with the correction compound significantly increased the cAMP- and genistein-mediated Isc compared to the 37°C controls.
[00270] 3. Identification of Potentiator Compounds
[00271] Typical protocol utilized a basolateral to apical membrane CI" concentration gradient. To set up this gradient, normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 μg/ml), whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large CI" concentration gradient across the epithelium. All experiments were performed 30 min after nystatin permeabilization. Forskolin (10 μΜ) and all test compounds were added to both sides of the cell culture inserts. The efficacy of the putative AF508-CFTR potentiators was compared to that of the known potentiator, genistein.
[00272] 4. Solutions
Basolateral solution (in mM): NaCl (135), CaCl2 (1.2), MgCl2 (1.2), K2HP04
(2.4), KHP04 (0.6), N-2-hydroxyethylpiperazine- N'-2-ethanesulfonic acid (HEPES) (10), and dextrose (10). The solution was titrated to pH
7.4 with NaOH.
Apical solution (in mM): Same as basolateral solution with NaCl replaced with Na Gluconate (135).
[00273] 5. Cell Culture
[00274] Fisher rat epithelial (FRT) cells expressing AF508-CFTR (FRT AF508-™) werg used for Ussing chamber experiments for the putative AF508-CFTR modulators identified from our optical assays. The cells were cultured on Costar Snapwell cell culture inserts and cultured for five days at 37 °C and 5% C02 in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Prior to use for characterizing the potentiator activity of compounds, the cells were incubated at 27 °C for 16 - 48 hrs to correct for the AF508-CFTR. To determine the activity of corrections compounds, the cells were incubated at 27 °C or 37 °C with and without the compounds for 24 hours.
[00275] 6. Whole-cell recordings
The macroscopic AF508-CFTR current (IAFSOS) in temperature- and test compound- corrected NIH3T3 cells stably expressing AF508-CFTR were monitored using the perforated- patch, whole-cell recording. Briefly, voltage-clamp recordings of IAFSOS were performed at room temperature using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). All recordings were acquired at a sampling frequency of 10 kHz and low- pass filtered at 1 kHz. Pipettes had a resistance of 5 - 6 ΜΩ when filled with the intracellular solution. Under these recording conditions, the calculated reversal potential for CI" (Eci) at room temperature was -28 mV. All recordings had a seal resistance > 20 GQ and a series resistance < 15 ΜΩ. Pulse generation, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A/D interface in conjunction with Clampex 8 (Axon Instruments Inc.). The bath contained < 250 μΐ of saline and was continuously perifused at a rate of 2 ml/min using a gravity-driven perfusion system.
[00276] 7. Identification of Correction Compounds
[00277] To determine the activity of correction compounds for increasing the density of functional AF508-CFTR in the plasma membrane, we used the above-described perforated- patch-recording techniques to measure the current density following 24-hr treatment with the correction compounds. To fully activate AF508-CFTR, 10 μΜ forskolin and 20 μΜ genistein were added to the cells. Under our recording conditions, the current density following 24-hr incubation at 27°C was higher than that observed following 24-hr incubation at 37 °C. These results are consistent with the known effects of low-temperature incubation on the density of AF508-CFTR in the plasma membrane. To determine the effects of correction compounds on CFTR current density, the cells were incubated with 10 μΜ of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 μΜ of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C controls.
[00278] 8. Identification of Potentiator Compounds
[00279] The ability of AF508-CFTR potentiators to increase the macroscopic AF508- CFTR CI" current (IAFSOS) in NIH3T3 cells stably expressing AF508-CFTR was also investigated using perforated-patch-recording techniques. The potentiators identified from the optical assays evoked a dose-dependent increase in IAFSOS with similar potency and efficacy observed in the optical assays. In all cells examined, the reversal potential before and during potentiator application was around -30 mV, which is the calculated EQ (-28 mV).
[00280] 9. Solutions
Intracellular solution (in mM): Cs-aspartate (90), CsCl (50), MgCl2 (1), HEPES
(10), and 240 μg/ml amphotericin-B (pH adjusted to 7.35 with CsOH).
Extracellular solution (in mM): N-methyl-D-glucamine (NMDG)-Cl (150),
MgCl2 (2), CaCl2 (2), HEPES (10) (pH adjusted to 7.35 with HC1).
[00281] 10. Cell Culture
[00282] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for whole- cell recordings. The cells are maintained at 37 °C in 5% C02 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For whole-cell recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 °C for measuring the activity of correctors.
[00283] 11. Single-channel recordings
[00284] The single-channel actdivities of temperature-corrected AF508-CFTR stably expressed in NIH3T3 cells and activities of potentiator compounds were observed using excised inside-out membrane patch. Briefly, voltage-clamp recordings of single-channel activity were performed at room temperature with an Axopatch 200B patch-clamp amplifier (Axon
Instruments Inc.). All recordings were acquired at a sampling frequency of 10 kHz and low- pass filtered at 400 Hz. Patch pipettes were fabricated from Corning Kovar Sealing #7052 glass (World Precision Instruments, Inc., Sarasota, FL) and had a resistance of 5 - 8 ΜΩ when filled with the extracellular solution. The AF508-CFTR was activated after excision, by adding 1 mM Mg-ATP, and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI). After channel activity stabilized, the patch was perifused using a gravity- driven microperfusion system. The inflow was placed adjacent to the patch, resulting in complete solution exchange within 1 - 2 sec. To maintain AF508-CFTR activity during the rapid perifusion, the nonspecific phosphatase inhibitor F" (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipette potential (Vp) was maintained at 80 mV.
[00285] Channel activity was analyzed from membrane patches containing≤ 2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To determine the single-channel current amplitude, the data recorded from 120 sec of AF508-CFTR activity was filtered "off-line" at 100 Hz and then used to construct all-point amplitude histograms that were fitted with multigaussian functions using Bio-Patch Analysis software (Bio-Logic Comp. France). The total microscopic current and open probability (P0) were determined from 120 sec of channel activity. The P0 was determined using the Bio-Patch software or from the relationship P0 = I/i(N), where I = mean current, i = single-channel current amplitude, and N = number of active channels in patch.
[00286] 12. Solutions
Extracellular solution (in mM): NMDG (150), aspartic acid (150), CaCl2 (5),
MgCl2 (2), and HEPES (10) (pH adjusted to 7.35 with Tris base).
Intracellular solution (in mM): NMDG-C1 (150), MgCl2 (2), EGTA (5), TES
(10), and Tris base (14) (pH adjusted to 7.35 with HC1).
[00287] 13. Cell Culture
[00288] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for excised-membrane patch-clamp recordings. The cells are maintained at 37 °C in 5% C02 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For single channel recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine- coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use.
[00289] Using the procedures described above, the activity, i.e., EC50s, of Compound 1 has been measured and is shown in Table 11.
Table 11.
Figure imgf000078_0001

Claims

We claim:
1. A method for preparing a compound of formula I:
Figure imgf000079_0001
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl,
-Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, - CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
m is an integer from 0 to 3 inclusive;
comprising the steps of
b) reacting a compound of formula IA in a first organic solvent
Figure imgf000079_0002
IA
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
Hal is a halide;
with a compound of formula IB:
Figure imgf000080_0001
IB wherein R is hydrogen or Ci_6 aliphatic, to form a compound of formula IC:
Figure imgf000080_0002
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive; and b) removing the -C02R group from compound IC in a second organic solvent a compound of formula I.
2. The method of claim 1, wherein ring A is a fused heterocycloalkyl or heteroaryl.
3. The method of claim 1, wherein ring A is
Figure imgf000081_0001
.
4. The method of claim 1, wherein X is CN.
5. The method of claim 1, wherein X is C02Et.
6. The method of any one of claims 1 to 5, wherein RJ is a Ci_6 aliphatic.
7. The method of any one of claims 1 to 6, wherein Hal is Br.
8. The method of any one of claims 1 to 7, wherein the first organic solvent is an aprotic solvent.
9. The method of any one of claims 1 to 8, wherein the first organic solvent is toluene.
10. The method of any one of claims 1 to 9, wherein step a) is carried out in the presence of a palladium catalyst.
11. The method of any one of claims 1 to 10, wherein step a) is carried out in the presence of a palladium catalyst selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2,
tetrakis(triphenylphosphine)palladium(0) or tris(dibenzylideneacetone)dipalladium(0).
12. The method of any one of claims 1 to 11, wherein step a) is carried out in the presence of
Pd(dba)2.
The method of any one of claims 1 to 12, wherein step a) is carried out at about 50 °C to
90 °C.
14. The method of any one of claims 1 to 13, wherein step a) is carried out at about 70 °C.
15. The method of any one of claims 1 to 14, wherein the second organic solvent is an aprotic solvent.
16. The method of any one of claims 1 to 15, wherein the second organic solvent is dimethy lsulfoxide .
17. The method of any one of claims 1 to 16, wherein step b) is carried out in the presence of an inorganic acid.
18. The method of any one of claims 1 to 17, wherein step b) is carried out at about 55 °C to 95 °C.
19. The method of any one of claims 1 to 18, wherein step b) is carried out at about 75 °C.
20. A method for preparing a compound of formula II:
Figure imgf000082_0001
II wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Hal is a halide;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; comprising the steps of
a) reacting a compound of formula IIA in a first organic solvent
Figure imgf000082_0002
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
Hal is a halide;
with a compound of formula IIB:
Figure imgf000083_0001
IIB
wherein
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
RJ is hydrogen or Ci_6 aliphatic, to form a compound of formula IIC:
Figure imgf000083_0002
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and m is an integer from 0 to 3 inclusive;
b) removing the -C02RJ group from compound IIC in a second organic solvent to form a compound of formula I:
Figure imgf000084_0001
I
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
m is an integer from 0 to 3 inclusive;
c) reacting a compound of formula I with a compound of formula IID in the presence of a base:
Figure imgf000084_0002
IID wherein, independently for each occurrence:
Hal is a halide; and q is an integer from 0 to 3 inclusive; to produce a compound of formula HE:
Figure imgf000085_0001
HE wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; m is an integer from 0 to 3 inclusive;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
n is an integer from 1 to 4 inclusive; d) sequentially reacting a compound of formula HE with a hydroxide base and acid to form a compound of formula IIF:
Figure imgf000085_0002
IIF wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; and
e) reacting a compound of formula IIF with a halogenating agent in a third organic solvent to form a compound of formula II.
21. The method of claim 20, wherein in step a), the first organic solvent is an aprotic solvent.
22. The method of any one of claim 20 or 21, wherein in step a), the first organic solvent is toluene.
23. The method of any one of claims 20 to 22, wherein in step a), Hal is Br.
24. The method of any one of claims 20 to 23, wherein in step a), ring A is a fused heterocyclic or heteroaryl ring.
25. The method of any one of claims 20 to 24, wherein in step a), ring A is
Figure imgf000086_0001
26. The method of any one of claims 20 to 25, wherein in step a), X is CN.
27. The method of any one of claims 20 to 26, wherein in step a) X is C02Et.
28. The method of any one of claims 20 to 27, wherein in step a) RJ is Et.
29. The method of any one of claims 20 to 28, wherein in formula IIC, ring A is
Figure imgf000086_0002
30. The method of any one of claims 20 to 29, wherein in step b), the second solvent is an aprotic solvent.
31. The method of any one of claims 20 to 30, wherein in step b), the second solvent is dimethy lsulfoxide .
32. The method of any one of claims 20 to 31 , wherein in formula I, ring A is
Figure imgf000087_0001
, m is 0, and X is CN.
33. The method of any one of claims 20 to 32, wherein in step c), the base is an inorganic base.
34. The method of any one of claims 20 to 33, wherein in formula IID, one Hal is CI and the other Hal is Br.
35. The method of any one of claims 20 to 34, wherein in step d), the base is NaOH.
36. The method of any one of claims 20 to 35, wherein in step d), the acid is HC1.
37. The method of any one of claims 20 to 36, wherein in step d), reaction with a hydroxide base takes place at about 60 °C to 100 °C.
38. The method of any one of claims 20 to 37, wherein in formula HE, ring A is
Figure imgf000087_0002
m is 0, n is 1 , and X is CN.
39. The method of any one of claims 20 to 38, wherein in step e), the third organic solvent is an aprotic solvent.
40. The method of any one of claims 20 to 39, wherein in step e), the third organic solvent is toluene.
41. The method of any one of claims 20 to 40, wherein in step e), the halogenating agent is
SOCl2.
42. The method of any one of claims 20 to 41, wherein step e) takes place at about 40 °C to
80 °C.
43. The method of any one of claims 20 to 42, wherein in formula IIF, ring A is
Figure imgf000088_0001
m is 0, and n is 1.
44. The method of any one of claims 20 to 43, wherein in formula II, ring A is
Figure imgf000088_0002
m is 0, n is 1, and Hal is CI.
45. A method of preparing a compound of formula III:
Figure imgf000088_0003
III wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group; and o is an integer from 0 to 3; comprising the steps of:
a) reacting a compound of formula IIIA:
Figure imgf000088_0004
IIIA wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; and
o is an integer from 0 to 3;
with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:
Figure imgf000089_0001
wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; and
Hal is a halide;
b) reacting the compound of formula IIIB in a second organic solvent with a compound of formula IIIC:
IIIC
wherein:
P is a protecting group;
followed by reduction and treatment with acid to form a compound of formula HID:
Figure imgf000090_0001
HID wherein:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -C haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3;
Hal is a halide;
P is a protecting group; and
Θ
A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
Figure imgf000090_0002
IIID-a wherein
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; Hal is a halide; and
P is a protecting group;
d) reacting a compound of formula IIID-a in a third organic solvent with a compound of formula HIE:
Figure imgf000091_0001
HIE
wherein, independently for each occurrence:
P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III.
46. The method of claim 45, wherein in formula IIIA, o is 1 and R2 is F.
47. The method of claim 45 or 46, wherein in step a), the halogenating reagent is N- bromosuccinimide.
48. The method of any one of claims 45 to 47, wherein in step a), the first organic solvent is an aprotic solvent.
49. The method of any one of claims 45 to 48, wherein in step a), the first organic solvent is ethyl acetate.
50. The method of any one of claims 45 to 49, wherein step a) takes place at about 2 °C to 42 °C.
51. The method of any one of claims 45 to 50, wherein in formula IIIB, o is 1 , R2 is F, and Hal is Br.
52. The method of any one of claims 45 to 51 , wherein in formula IIIC, P is benzyl.
53. The method of any one of claims 45 to 52, wherein in step b), the second organic solvent is an aprotic solvent.
54. The method of any one of claims 45 to 53, wherein in step b), the second organic solvent is toluene.
55. The method of any one of claims 45 to 54, wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C.
56. The method of any one of claims 45 to 55, wherein in step b), reduction is carried out with hydrogen.
57. The method of any one of claims 45 to 56, wherein in step b), the acid is p- toluenesulfonic acid.
58. The method of any one of claims 45 to 57, wherein in formula HID, o is 1, R2 is F, Hal is
Θ
Br, A is Tos", and P is benzyl.
59. The method of any one of claims 45 to 58, wherein in formula HIE, R3 is
C(CH3)2CH20(benzyl).
60. The method of any one of claims 45 to 59, wherein in step c) the base is an inorganic base.
61. The method of any one of claims 45 to 60, wherein in step d), the third organic solvent is an aprotic solvent.
62. The method of any one of claims 45 to 61, wherein in step d), the third organic solvent is acetonitrile.
63. The method of any one of claims 45 to 62, wherein step d) takes place at about 60 °C to 100 °C.
64. The method of any one of claims 45 to 63, wherein in step d), the catalyst is a palladium catalyst.
65. The method of any one of claims 45 to 64, wherein in step d, the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2, tetrakis(triphenylphosphine)palladium(0), (MeCN)2PdCl2, or tris(dibenzylideneacetone)dipalladium(0).
66. The method of any one of claims 45 to 65, wherein in step d, the catalyst is palladium(II)acetate.
A method of preparing a compound of formula IV
Figure imgf000093_0001
IV
wherein, independently for each occurrence:
ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri and R2 is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
R3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group; m is an integer from 0 to 3 inclusive;
n is an integer from 1 to 4 inclusive; and o is an integer from 1 to 3 inclusive; comprising the steps of:
a) reacting a compound of formula IIIA:
Figure imgf000093_0002
IIIA wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; and
o is an integer from 0 to 3;
with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:
Figure imgf000094_0001
wherein, independently for each occurrence:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; and
Hal is a halide;
b) reacting the compound of formula IIIB in a second organic solvent with a compound of formula IIIC:
IIIC
wherein:
P is a protecting group;
followed by reduction and treatment with acid to form a compound of formula HID:
Figure imgf000095_0001
HID wherein:
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -C haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3;
Hal is a halide;
P is a protecting group; and
Θ
A is an anion; c) neutralizing a compound of formula HID in the presence of a base to form a compound of formula IIID-a:
Figure imgf000095_0002
IIID-a wherein
R2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, C02RJ, -NRJS02N(RJ)2, -COCORJ ; RJ is hydrogen or Ci_6 aliphatic;
o is an integer from 0 to 3; Hal is a halide; and
P is a protecting group;
d reacting a compound of formula HID in a third organic solvent with a compound of formula HIE:
Figure imgf000096_0001
HIE
wherein, independently for each occurrence:
P 3 is a Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl; in the presence of a catalyst to form a compound of formula III:
Figure imgf000096_0002
III
wherein, independently for each occurrence:
P 2 is -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN, -Ci_4haloalkyl, -Ci_4haloalkoxy,
-C(0)N(RJ)2, -NPvJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, - C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
R3 is Ci_6 aliphatic optionally substituted with OH, OP, -0-Ci_6 aliphatic, aryl, heteroaryl, -O-aryl, or -O-heteroaryl;
P is a protecting group; and
o is an integer from 0 to 3; e reacting the compound of formula III in a fourth organic solvent with a compound of formula II:
Figure imgf000097_0001
II
wherein, independently for each occurrence: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; Hal is a halide;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic; m is an integer from 0 to 3 inclusive; and
n is an integer from 1 to 4 inclusive; to form the compound of formula IV.
68. The method of claim 67, wherein in formula IV, ring A is
Figure imgf000097_0002
.
69. The method of claim 67 or 68, wherein in formula IV, o is 1 and R2 is F.
70. The method of any one of claims 67 to 69, wherein in formula IV, P is benzyl.
71. The method of any one of claims 67 to 70, wherein in formula IV, R3 is a C4 aliphatic optionally substituted with OP.
72. The method of any one of claims 67 to 71, wherein in formula IV, R3 is — OP .
3. The method of any one of claims 67 to 72, wherein in formula IV, R3 is
Figure imgf000098_0001
74. The method of any one of claims 67 to
m is 0, n is 1, o is 1 and R2 is F, P is benzyl
Figure imgf000098_0002
75. The method of any one of claims 67 to 74, wherein in step a), the halogenating reagent is N-bromosuccinimide .
76. The method of any one of claims 67 to 75, wherein in step a), the first organic solvent is an aprotic solvent.
77. The method of any one of claims 67 to 76, wherein in step a), the first organic solvent is ethyl acetate.
78. The method of any one of claims 67 to 77, wherein step a) takes place at about 2 °C to 42
°C.
79. The method of any one of claims 67 to 78, wherein in formula IIIB, o is 1, R2 is F, and Hal is Br.
80. The method of any one of claims 67 to 79, wherein in formula IIIC, P is benzyl.
81. The method of any one of claims 67 to 80, wherein in step b), the second organic solvent is an aprotic solvent.
82. The method of any one of claims 67 to 81, wherein in step b), the second organic solvent is toluene.
83. The method of any one of claims 67 to 82, wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 °C to 100 °C.
84. The method of any one of claims 67 to 83, wherein in step b), reduction is carried out with hydrogen.
85. The method of any one of claims 67 to 84, wherein in step b), the acid is p- toluenesulfonic acid.
86. The method of any one of claims 67 to 85, wherein in formula HID, o is 1, R2 is F, Hal is
Θ
Br, A is Tos", and P is benzyl.
87. The method of any one of claims 67 to 86, wherein in formula HIE, R3 is
C(CH3)2CH20(benzyl).
88. The method of any one of claims 67 to 87, wherein in step c), the base is an inorganic base.
89. The method of any one of claims 67 to 88, wherein in step d, the third organic solvent is an aprotic solvent.
90. The method of any one of claims 67 to 89, wherein in step d, the third organic solvent is acetonitrile.
91. The method of any one of claims 67 to 90, wherein step d takes place at about 60 °C to 100 °C.
92. The method of any one of claims 67 to 91, wherein in step d, the catalyst is a palladium catalyst.
93. The method of any one of claims 67 to 92, wherein in step d, the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2, tetrakis(triphenylphosphine)palladium(0), (MeCN)2PdCl2, or tris(dibenzylideneacetone)dipalladium(0).
94. The method of any one of claims 67 to 93, wherein in step d, the catalyst is
palladium(II)acetate.
95. The method of any one of claims 67 to 94, wherein in step e, ring A is
Figure imgf000099_0001
, m is 0, n is 1, and Hal is CI.
96. The method of any one of claims 67 to 95, wherein in step e, the fourth organic solvent is an aprotic solvent.
97. The method of any one of claims 67 to 96, wherein in step e, the fourth organic solvent is dichloromethane.
98. The method of any one of claims 67 to 97, wherein step e takes place at about -20 °C to
20 °C.
99. The method of any one of claims 67 to 98, wherein in step e, the compound of formula II is prepared in situ by halogenating the acid precursor and reacted with the compound of formula III without isolation.
100. The method of any one of claims 67 to 99, further comprising removing the two protecting groups from the compound of formula IV to form a compound of formula IVA:
Figure imgf000100_0001
IVA.
101. The method of claim 100, wherein the protecting groups are removed by hydrogenation.
102. A method of preparing Compound 1 :
Figure imgf000100_0002
1 comprising the steps of:
a) reacting compound 2:
Figure imgf000100_0003
with a brominating reagent to form a compound 3 :
Figure imgf000101_0001
3
b) reacting compound 3 with compound 4
L ^OBn followed by reduction to form compound 5 :
Figure imgf000101_0002
followed by neutralizing compound 5 with a base to give compound 5a:
Figure imgf000101_0003
c) reacting compound 5awith compound 6
Figure imgf000101_0004
in the presence of a catalyst to form compound 7:
Figure imgf000102_0001
d) reacting compound 7 with compound 8
Figure imgf000102_0002
8
to form compound 9:
Figure imgf000102_0003
9
and e) removing the two Bn protecting groups to form Compound 1.
103. The method of claim 102, wherein in step a), the brominating agent is N- bromosuccinimide.
104. The method of claim 102 or 103, wherein in setp b), the reduction is carried out with hydrogen.
105. The method of any one of claims 102 to 104, wherein in step c), the catalyst is a palladium catalyst.
106. The method of any one of claims 102 to 105, wherein in step c), the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl2, Pd(dba)2, tetrakis(triphenylphosphine)palladium(0), (MeCN)2PdCl2, or tris(dibenzylideneacetone)dipalladium(0).
107. The method of any one of claims 102 to 106, wherein in step c), the catalyst is palladium(II)acetate.
108. The method of any one of claims 102 to 107, wherein in step d), compound 8 is made in situ by halogenating the acid precursor without isolation.
109. The method of any one of claims 102 to 108, wherein in step e), the Bn protecting groups are removed by hydrogenation.
110. A compound of formula 23 :
Figure imgf000103_0001
wherein: ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
Ri is independently selected from -RJ, -ORJ, -N(RJ)2, -N02, halogen, -CN,
-Ci_4haloalkyl, -Ci_4haloalkoxy, -C(0)N(RJ)2, -NRJC(0)RJ, -SORJ, -S02RJ, -S02N(RJ)2, -NRJS02RJ, -CORJ, -C02RJ, -NRJS02N(RJ)2, -COCORJ ;
RJ is hydrogen or Ci_6 aliphatic;
X is CN or C02R;
R is Ci_6 aliphatic or aryl; and
m is an integer from 0 to 3 inclusive.
111. The compound of claim 110, wherein ring A is a fused heterocycloalkyl or heteroaryl.
112 The compound of any one of claims 110 to 1 11, wherein ring A is
Figure imgf000103_0002
113 The compound of any one of claims 110 to 112, wherein X is CN.
114 The compound of any one of claims 110 to 113, wherein X is C02Et.
15. The compound of any one of claims 1 10 to 1 14, wherein RJ is Ci_6 aliphatic.
16. The compound
Figure imgf000104_0001
17. The compound
Figure imgf000104_0002
PCT/US2011/033396 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds WO2011133751A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
EP18173910.3A EP3381899B1 (en) 2010-04-22 2011-04-21 Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US13/642,642 US9035072B2 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
KR1020127030452A KR20130056244A (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
KR1020197015032A KR20190061096A (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
CA2797118A CA2797118C (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
CN201180031319.5A CN103038214B (en) 2010-04-22 2011-04-21 Prepare the method for cycloalkyl carboxamides base-benzazolyl compounds
CA3108488A CA3108488A1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
AU2011242712A AU2011242712B2 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
JP2013506299A JP2013525371A (en) 2010-04-22 2011-04-21 Method for producing cycloalkylcarboxamide-indole compound
SG2012078374A SG184987A1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
MX2016009018A MX353408B (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds.
NZ603721A NZ603721A (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
RU2012149691/04A RU2569678C2 (en) 2010-04-22 2011-04-21 Method for producing cycloalkylcarboxamido-indole compounds
EP11729195.5A EP2560954B1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
ES11729195.5T ES2608474T3 (en) 2010-04-22 2011-04-21 Production process of indole compounds cycloalkylcarboxamido
KR1020167010394A KR101984225B1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
BR112012027056A BR112012027056B8 (en) 2010-04-22 2011-04-21 Process of production of cycloalkylcarboxamido-indole compounds
MX2015003252A MX342288B (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds.
MX2012012204A MX2012012204A (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds.
IL222539A IL222539A0 (en) 2010-04-22 2012-10-18 Process of producing cycloalkylcarboxamido-indole compounds
IL236209A IL236209B (en) 2010-04-22 2014-12-11 Process of producing cycloalkylcarboxamido-indole compounds
US14/687,286 US10071979B2 (en) 2010-04-22 2015-04-15 Process of producing cycloalkylcarboxamido-indole compounds
AU2016202569A AU2016202569B2 (en) 2010-04-22 2016-04-22 Process of producing cycloalkylcarboxamido-indole compounds
US16/059,724 US20190210991A1 (en) 2010-04-22 2018-08-09 Process of producing cycloalkylcarboxamido-indole compounds
IL268953A IL268953B (en) 2010-04-22 2019-08-27 Process of producing cycloalkylcarboxamido-indole compounds
US17/003,051 US20210238158A1 (en) 2010-04-22 2020-08-26 Process of producing cycloalkylcarboxamido-indole compounds

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US32709910P 2010-04-22 2010-04-22
US32709110P 2010-04-22 2010-04-22
US32709510P 2010-04-22 2010-04-22
US32705710P 2010-04-22 2010-04-22
US61/327,095 2010-04-22
US61/327,091 2010-04-22
US61/327,099 2010-04-22
US61/327,057 2010-04-22
US32951010P 2010-04-29 2010-04-29
US32950010P 2010-04-29 2010-04-29
US32949310P 2010-04-29 2010-04-29
US61/329,500 2010-04-29
US61/329,493 2010-04-29
US61/329,510 2010-04-29
US33387010P 2010-05-12 2010-05-12
US61/333,870 2010-05-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/642,642 A-371-Of-International US9035072B2 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
US14/687,286 Division US10071979B2 (en) 2010-04-22 2015-04-15 Process of producing cycloalkylcarboxamido-indole compounds

Publications (3)

Publication Number Publication Date
WO2011133751A2 true WO2011133751A2 (en) 2011-10-27
WO2011133751A3 WO2011133751A3 (en) 2012-01-12
WO2011133751A9 WO2011133751A9 (en) 2012-02-16

Family

ID=44278819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033396 WO2011133751A2 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds

Country Status (18)

Country Link
US (4) US9035072B2 (en)
EP (3) EP3381899B1 (en)
JP (4) JP2013525371A (en)
KR (3) KR20190061096A (en)
CN (2) CN103038214B (en)
AR (1) AR081333A1 (en)
AU (2) AU2011242712B2 (en)
BR (1) BR112012027056B8 (en)
CA (2) CA3108488A1 (en)
ES (2) ES2608474T3 (en)
HK (2) HK1218419A1 (en)
IL (3) IL222539A0 (en)
MX (3) MX2012012204A (en)
NZ (2) NZ734535A (en)
RU (2) RU2569678C2 (en)
SG (3) SG184987A1 (en)
TW (3) TWI518082B (en)
WO (1) WO2011133751A2 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534236A (en) * 2011-11-08 2014-12-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Modifiers for ATP-binding cassette transporters
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US10167278B2 (en) 2014-12-31 2019-01-01 Auspex Pharmaceuticals, Inc. Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
WO2019010092A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018353A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2020102346A1 (en) 2018-11-14 2020-05-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US10751363B2 (en) 2015-03-23 2020-08-25 Algipharma As Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
US10758534B2 (en) 2014-10-06 2020-09-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
US10875846B2 (en) 2019-01-15 2020-12-29 Apotex Inc. Processes for the preparation of Tezacaftor and intermediates thereof
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2021030556A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2021030555A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3835297A1 (en) * 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthesis and intermediates of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11186566B2 (en) 2016-09-30 2021-11-30 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2022032068A1 (en) 2020-08-07 2022-02-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2022076628A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076629A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076624A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076625A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076622A2 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076627A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076620A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022125826A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
WO2023150237A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023196429A1 (en) 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers
US12122788B2 (en) 2023-01-04 2024-10-22 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RU2006111093A (en) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (en) 2004-06-24 2023-10-31 Vertex Pharma atp link cassette carrier modulators
JP5143738B2 (en) 2005-08-11 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of cystic fibrosis membrane conductance regulator
ES2439736T3 (en) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP binding cassette transporters
HUE049976T2 (en) 2005-12-28 2020-11-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CN104447716A (en) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Modulators of CFTR
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
CA2705562C (en) 2007-11-16 2016-05-17 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
CN101910156B (en) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
PT2615085E (en) 2008-03-31 2015-10-09 Vertex Pharma Pyridyl derivatives as cftr modulators
CN102164587A (en) 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 Dosage units of 3-(6-(1-(2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
DK3150198T3 (en) 2010-04-07 2021-11-01 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) -CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIODIN-2-YL) BENZOIC ACID AND ADMINISTRATION
BR112012026257A2 (en) 2010-04-07 2017-03-14 Vertex Pharma solid forms of 3- (6- (1- (2-, 2-difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
MX2012012204A (en) * 2010-04-22 2012-12-05 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
CN109966264A (en) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 Pharmaceutical composition and its application
AR092857A1 (en) 2012-07-16 2015-05-06 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF (R) -1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- ( 1-HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANCARBOXAMIDE AND ADMINISTRATION OF THE SAME
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN107250113B (en) 2014-10-07 2019-03-29 弗特克斯药品有限公司 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP6494757B2 (en) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Process for high-throughput high performance liquid chromatography
US10604492B2 (en) 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
WO2018183367A1 (en) 2017-03-28 2018-10-04 Van Goor Fredrick F Methods of treating cystic fibrosis in patients with residual function mutations
CN111629730A (en) 2017-08-24 2020-09-04 加利福尼亚大学董事会 Ophthalmic pharmaceutical composition
EP3971186B1 (en) * 2019-06-19 2023-08-02 LG Chem, Ltd. Preparation method for indole or indazole compound
WO2020256430A1 (en) * 2019-06-19 2020-12-24 주식회사 엘지화학 Method for producing indole or indazole compound
CN110437125B (en) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 Preparation method of Tezacaftor intermediate II
CN113121358A (en) * 2019-12-31 2021-07-16 阜新金特莱氟化学有限责任公司 Preparation method of 2-bromo-5-fluoro-4-nitroaniline
CN111187197B (en) * 2020-01-13 2021-10-01 苏州旺山旺水生物医药有限公司 Synthesis method of Tezacaftor intermediate
EP4099991A4 (en) * 2020-02-05 2024-06-26 Laurus Labs Limited Novel processes for preparation of tezacaftor
CN113657599B (en) * 2021-08-20 2024-05-28 北京航空航天大学 Accident cause and effect reasoning method, device, electronic equipment and readable storage medium

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028480A2 (en) 2002-09-30 2004-04-08 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004080972A1 (en) 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
WO2004091502A2 (en) 2003-04-11 2004-10-28 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005035514A2 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
WO2005049018A1 (en) 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
WO2005094374A2 (en) 2004-03-30 2005-10-13 The Regents Of The University Of California Hydrazide-containing cftr inhibitor compounds and uses thereof
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006099256A2 (en) 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2006101740A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2006127588A2 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2007044560A2 (en) 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20090131492A1 (en) 2006-04-07 2009-05-21 Ruah Sara S Hadida Indole derivatives as CFTR modulators

Family Cites Families (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605382A (en) * 1975-06-04 1976-12-07 Sumitomo Chemical Co PROCESS FOR PREPARING INDOLE DERIVATIVES.
JPS5328173A (en) * 1976-08-06 1978-03-16 Zenyaku Kogyo Kk Novel phenylmethanenitro compound and its preparation
DE2735133C2 (en) 1977-08-04 1981-10-15 Universität Karlsruhe Institut für Elektrotechnische Grundlagen der Informatik, 7500 Karlsruhe Memory cell for non-destructive reading with 2 Josephson contacts
US4138397A (en) 1978-02-27 1979-02-06 Richardson-Merrell Inc. 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPS61103861A (en) * 1984-10-27 1986-05-22 Nitto Kasei Kk Preparation of aryl-substituted cyanoacetic acid ester
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JPH10213820A (en) 1997-01-31 1998-08-11 Canon Inc Liquid crystal element and liquid crystal device
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
KR20010014020A (en) 1997-06-21 2001-02-26 로셰 디아그노스틱스 게엠베하 Barbituric acid derivatives with antimetastatic and antitumor activity
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
JP2001525365A (en) 1997-12-11 2001-12-11 バイオケム・フアーマ・インコーポレーテツド Antiviral compounds
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
ATE496032T1 (en) 1999-02-24 2011-02-15 Hoffmann La Roche 4-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS
DE60028791T2 (en) 1999-09-10 2007-05-24 Novo Nordisk A/S MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES)
JP2003509430A (en) 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ Modulator of protein tyrosine phosphatase (PTPase)
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
IT1315267B1 (en) 1999-12-23 2003-02-03 Novuspharma Spa DERIVATIVES OF 2- (1H-INDOL-3-IL) -2-OXO-ACETAMIDES FOR ANTI-TUMOR ACTIVITY
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
DE10038019A1 (en) * 2000-08-04 2002-02-14 Bayer Ag Substituted triazolopyride (az) ine
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6562989B2 (en) * 2000-08-07 2003-05-13 Yale University Catalyst for aromatic C—O, C—N, and C—C bond formation
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AR030357A1 (en) 2000-08-18 2003-08-20 Lundbeck & Co As H DERIVATIVES 4 -, 5 -, 6 - AND 7-INDOL
US6550895B1 (en) 2000-10-20 2003-04-22 Silverbrook Research Pty Ltd Moving nozzle ink jet with inlet restriction
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2442654A1 (en) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Probes, systems, and methods for drug discovery
CN1300116C (en) 2001-04-16 2007-02-14 卫材株式会社 Novel 1H-indazole compound
CN1522246B (en) 2001-06-28 2010-04-21 辉瑞产品公司 Triamide-substituted indoles, benzofuranes and benzothiophenes
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003041649A2 (en) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors
JP2005518391A (en) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Amide derivatives as GK activators
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2003093498A1 (en) 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
TW200413372A (en) 2002-09-18 2004-08-01 Ono Pharmaceutical Co Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient
JP2004131393A (en) 2002-10-08 2004-04-30 Kowa Co Readily eluting pharmaceutical preparation
CA2501547A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
FR2846327B1 (en) 2002-10-25 2006-03-24 Merck Sante Sas N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DYSLIPIDEMIA AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
RS20050294A (en) 2002-11-02 2007-11-15 Sanofi-Aventis Deutschland Gmbh., Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
DE10251019A1 (en) 2002-11-02 2004-05-19 Aventis Pharma Deutschland Gmbh New pyrimidine-4,6-dicarboxamide derivatives, are selective collagenase inhibitors useful e.g. for treating degenerative joint diseases, connective tissue disorders or cancer
US20040146941A1 (en) 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE10300017A1 (en) 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Selective MMP 13 inhibitors
KR101145252B1 (en) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 Antibacterial agents
US6933311B2 (en) 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7531558B2 (en) 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
DE10306941A1 (en) 2003-02-18 2004-08-26 Merck Patent Gmbh New indolyl-substituted benzofuranyloxy-alkylamine derivatives, are 5-hydroxytryptamine reuptake inhibitors useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents
EP1720844B1 (en) 2003-04-03 2009-04-29 MERCK PATENT GmbH Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
US20050164951A1 (en) 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
DE10315377A1 (en) 2003-04-03 2004-10-14 Merck Patent Gmbh New carbonyl-substituted carbocyclic or heterocyclic compounds, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or tumors
JP4629657B2 (en) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 11β-hydroxysteroid dehydrogenase type 1 active compound
WO2005002519A2 (en) 2003-06-27 2005-01-13 Henry M.Jackson Foundation For The Advancement Of Military Medicine, Inc. Amphiphilic pyridinium compounds, method of making and use thereof
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2004265020B8 (en) 2003-08-15 2009-11-05 H. Lundbeck A/S Cyclopropyl derivatives as NK3 receptor antagonists
RU2006111093A (en) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005037802A1 (en) * 2003-10-16 2005-04-28 Sankyo Company, Limited 5-arylpyrimidine derivative
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co Antistress drug and medical use thereof
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
BRPI0507278A (en) 2004-01-30 2007-06-26 Vertex Pharma modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20050222271A1 (en) 2004-03-31 2005-10-06 Le Huang Novel amorphous form of memantine hydrochloride
FR2868417B1 (en) 2004-04-02 2006-06-23 Rhodia Chimie Sa PROCESS FOR FORMING CARBON-CARBON BOND
AU2005249154B2 (en) 2004-06-01 2011-02-10 Luminex Molecular Diagnostics, Inc. Method of detecting cystic fibrosis associated mutations
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
BR122018075478B8 (en) 2004-06-24 2023-10-31 Vertex Pharma atp link cassette carrier modulators
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
MX2007001215A (en) 2004-08-06 2007-04-17 Otsuka Pharma Co Ltd Aromatic compounds.
DE102004047254A1 (en) 2004-09-29 2006-04-13 Merck Patent Gmbh carbonyl
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
JPWO2006057448A1 (en) 2004-11-26 2008-06-05 武田薬品工業株式会社 Arylalkanoic acid derivatives
CA2599348C (en) 2005-02-25 2013-07-23 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
US20100120789A1 (en) 2005-03-24 2010-05-13 Nigel Vicker Compound
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
NZ561672A (en) * 2005-03-28 2010-04-30 Toyama Chemical Co Ltd Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof
JP2006282534A (en) 2005-03-31 2006-10-19 Fuji Photo Film Co Ltd Preparation method of amides
CA2604920A1 (en) 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
ES2367844T3 (en) 2005-08-11 2011-11-10 Vertex Pharmaceuticals, Inc. MODULATORS OF THE REGULATOR OF THE TRANSMEMBRANE CONDUCTANCE OF THE CHYSICAL FIBROSIS.
JP5143738B2 (en) 2005-08-11 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of cystic fibrosis membrane conductance regulator
CA2624220A1 (en) * 2005-09-29 2007-04-12 Wyeth 1- (1h- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)
EP1942732A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
ES2439736T3 (en) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP binding cassette transporters
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
BRPI0620292B1 (en) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. TRIAZOLOPYRIDAZINE COMPOUNDS AS KINASE MODULATORS, COMPOSITION, USE, COMBINATION AND PREPARATION PROCESS OF SUCH COMPOUND
US20090105272A1 (en) 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
HUE049976T2 (en) 2005-12-28 2020-11-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2856037C (en) 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
KR20140107691A (en) 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 Pharmaceutical compositions
CN101494979A (en) 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 Pharmaceutical compositions
JP2009530399A (en) 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Compounds and methods for the treatment of diseases associated with ER stress
RU2451018C2 (en) 2006-04-07 2012-05-20 Вертекс Фармасьютикалз Инкорпорейтед Modulators of atp-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2007249269A1 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2008020227A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
PL2081937T3 (en) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopyridazine protein kinase modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2118103B1 (en) 2006-11-03 2014-04-23 Vertex Pharmaceuticals Inc. Azaindole derivatives as cftr modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US20080132560A1 (en) 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
WO2008065732A1 (en) 2006-11-27 2008-06-05 Nippon Polyurethane Industry Co., Ltd. Process for production of modified isocyanate mixture containing allophanate bond and isocyanurate bond
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN104447716A (en) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Modulators of CFTR
ES2548292T3 (en) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
PT2178865E (en) 2007-07-19 2015-11-16 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
CN101821266B (en) 2007-09-14 2014-03-12 沃泰克斯药物股份有限公司 Modulators of cystic fibrosis transmembrane conductance regulator
NZ600865A (en) 2007-09-14 2014-01-31 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2217588A4 (en) 2007-11-02 2013-12-04 Methylgene Inc Inhibitors of histone deacetylase
CA2705562C (en) 2007-11-16 2016-05-17 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
AU2008327095B2 (en) 2007-11-22 2013-07-25 Ohara Pharmaceutical Co., Ltd. Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same
WO2009076141A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CN101910156B (en) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP5637859B2 (en) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Modulator of cystic fibrosis membrane conductance regulator
WO2009086426A2 (en) 2007-12-28 2009-07-09 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
PT2615085E (en) 2008-03-31 2015-10-09 Vertex Pharma Pyridyl derivatives as cftr modulators
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
WO2009129501A1 (en) 2008-04-18 2009-10-22 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
BRPI0911482A2 (en) 2008-04-24 2017-08-29 Bristol Myers Squibb Co USE OF EPOTHYLONE D IN THE TREATMENT OF TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER DISEASES
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP5575768B2 (en) 2008-08-13 2014-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド Pharmaceutical composition and its administration
US8895781B2 (en) 2008-09-04 2014-11-25 Georgetown University Transition metal-catalyzed C—H amination using unactivated amines
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
CN102164587A (en) 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 Dosage units of 3-(6-(1-(2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5645834B2 (en) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Modulator of cystic fibrosis membrane conductance regulator
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
EA018891B1 (en) * 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Modulators of cystic fibrosis transmembrane conductance regulator
JP5645835B2 (en) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ N- (4- (7-azabicyclo [2.2.1] heptane-7-yl) -2- (trifluoromethyl) phenyl) -4-oxo-5- (trifluoromethyl) -1,4-dihydro Solid form of quinoline-3-carboxamide
UA121188C2 (en) 2008-11-06 2020-04-27 Вертекс Фармасьютікалз Інкорпорейтед ATV-CONNECTING CASSETTE CONVEYOR MODULATORS
UA104876C2 (en) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Modulators of atp-binding cassette transporters
AR074231A1 (en) 2008-11-27 2010-12-29 Boehringer Ingelheim Int DERIVATIVES OF 6, 7, 8, 9-TETRAHIDRO-5H-1, 4, 7, 10A-TETRAAZA-CICLOHEPT [F] INDENO, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE IN THE 5-HT2C RECEPTOR AGONISM AND PROCESSES FOR PREPARE THEM.
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
KR20100101054A (en) 2009-03-07 2010-09-16 주식회사 메디젠텍 Composition for treating or preventing nuclear export of gsk3- mediated disease including compound for inhibiting nuclear export of gsk3
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
CA2755969C (en) 2009-03-20 2018-05-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
GB0905641D0 (en) 2009-04-01 2009-05-13 Serodus As Compounds
ES2475091T3 (en) 2009-04-16 2014-07-10 Centro Nacional De Investigaciones Oncol�Gicas (Cnio) Imidazopyrazines as protein kinase inhibitors
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
EP2264012A1 (en) 2009-06-03 2010-12-22 Bayer CropScience AG Heteroarylamidines and their use as fungicides
KR101256018B1 (en) 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
WO2011029832A1 (en) 2009-09-09 2011-03-17 Vifor (International) Ag Novel thiazol and oxazol hepcidine antagonists
KR20120083416A (en) 2009-09-17 2012-07-25 버텍스 파마슈티칼스 인코포레이티드 Process for preparing azabicyclic compounds
US9334230B2 (en) 2009-09-18 2016-05-10 Nanyang Technological University Process of forming an amide
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CN102648182A (en) 2009-10-23 2012-08-22 沃泰克斯药物股份有限公司 Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
CA2778493A1 (en) 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102883607B (en) 2010-03-01 2015-07-22 Gtx公司 Compounds for treatment of cancer
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
CN103180298A (en) 2010-03-19 2013-06-26 沃泰克斯药物股份有限公司 Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydr o-4-oxoquinoline-3-carboxamide
PT2826776T (en) * 2010-03-25 2021-02-01 Vertex Pharma Solid amorphous form of (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide
US8802868B2 (en) * 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026257A2 (en) 2010-04-07 2017-03-14 Vertex Pharma solid forms of 3- (6- (1- (2-, 2-difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
DK3150198T3 (en) 2010-04-07 2021-11-01 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) -CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIODIN-2-YL) BENZOIC ACID AND ADMINISTRATION
EP2560649A1 (en) * 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX2012012204A (en) * 2010-04-22 2012-12-05 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
EP2560651A1 (en) * 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
NZ603043A (en) * 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
EP2386606B1 (en) 2010-04-30 2018-03-21 Total Marketing Services Use of organogelator derivatives in bituminous compositions to improve the resistance thereof to chemical attacks
US8404849B2 (en) 2010-05-20 2013-03-26 Vertex Pharmaceuticals Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US9051346B2 (en) 2010-05-20 2015-06-09 Cempra Pharmaceuticals, Inc. Process for preparing triazole-containing ketolide antibiotics
AU2011255237A1 (en) 2010-05-20 2012-11-29 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
UA110113C2 (en) 2010-07-29 2015-11-25 BICYCLIC AZAGETEROCYCLIC CARBOXAMIDES
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2013002035A (en) * 2010-08-23 2013-03-25 Vertex Pharma Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dio xol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-met hylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof.
RU2013113627A (en) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед PHARMACEUTICAL COMPOSITION AND ITS INTRODUCTION
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2012079583A1 (en) 2010-12-15 2012-06-21 Aarhus Universitet System providing controlled delivery of gaseous co for carbonylation reactions
WO2012116135A2 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (en) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 Cyclohexanes derivant, its preparation method and in application pharmaceutically
HUE047354T2 (en) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Deuterated derivatives of ivacaftor
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
CN104159890B (en) 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 Composition, method and system for synthesizing and using developer
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
CN103946221B (en) 2011-09-16 2016-08-03 诺华股份有限公司 For treating the heterocyclic compound of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
AU2012332225A1 (en) 2011-11-02 2014-05-15 Vertex Pharmaceuticals Incorporated Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
ME02650B (en) * 2011-11-08 2017-06-20 Vertex Pharma Modulators of atp-binding cassette transporters
US20140127901A1 (en) * 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
WO2013086131A1 (en) 2011-12-06 2013-06-13 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza a
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
EP2606726A1 (en) 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
CA2862859C (en) 2012-01-25 2022-08-02 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN109966264A (en) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 Pharmaceutical composition and its application
JP2015518504A (en) 2012-04-03 2015-07-02 スリーエム イノベイティブ プロパティズ カンパニー Crosslinkable composition containing photobase generator
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8888905B2 (en) 2012-04-26 2014-11-18 Xerox Corporation Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
US9528016B2 (en) 2012-04-26 2016-12-27 Xerox Corporation Phase change inks comprising crystalline amides
US20130284054A1 (en) 2012-04-26 2013-10-31 Xerox Corporation Rapid solidifying crystalline-amorphous inks
CA2813472A1 (en) 2012-04-26 2013-10-26 Xerox Corporation Rapid solidifying crystalline-amorphous inks
US9228101B2 (en) 2012-04-26 2016-01-05 Xerox Corporation Rapidly crystallizing phase change inks and methods for forming the same
GB2502624A (en) 2012-06-01 2013-12-04 Univ East Anglia Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
WO2013184198A1 (en) 2012-06-08 2013-12-12 Massachusetts Institute Of Technology Phosphine-ligated palladium sulfonate palladacycles
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
FR2992317B1 (en) 2012-06-22 2016-05-13 Diverchim PROCESS FOR THE PREPARATION OF CHIRAL PEPTIDES
WO2014002106A1 (en) 2012-06-25 2014-01-03 Cadila Healthcare Limited Novel compounds for the treatment of dyslipidemia and related diseases
US20150209448A1 (en) 2012-07-12 2015-07-30 Proqr Therapeutics N.V. Exon replacement with stabilized artificial rnas
EP2852668B1 (en) 2012-07-12 2016-04-27 ProQR Therapeutics II B.V. Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
AR092857A1 (en) 2012-07-16 2015-05-06 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF (R) -1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- ( 1-HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANCARBOXAMIDE AND ADMINISTRATION OF THE SAME
CN104812382A (en) 2012-09-20 2015-07-29 坦普尔大学 Substituted alkyl diaryl derivatives, methods of preparation and uses
CN104769465A (en) 2012-10-29 2015-07-08 柯尼卡美能达株式会社 Phase difference film, circularly polarizing plate, and image forming device
IL283276B2 (en) 2012-11-02 2024-05-01 Vertex Pharma Compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and uses thereof
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
JP6146990B2 (en) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド Deuterated CFTR enhancer
BR112015011441A2 (en) 2012-11-20 2017-07-11 Merial Inc anthelmintic compositions and compounds and methods of their use
ITMI20122065A1 (en) 2012-12-03 2014-06-04 Univ Padova USE OF CFTR CORRECTORS IN THE TREATMENT OF STRUCTURAL MUSCLE PATHOLOGIES
EP2929346A1 (en) 2012-12-05 2015-10-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Diagnosis of cystic fibrosis
EP2928532A4 (en) 2012-12-07 2016-06-29 Parion Sciences Inc Nasal cannula for delivery of aerosolized medicaments
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US20140296164A1 (en) 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
AU2014264936B2 (en) 2013-05-07 2018-09-27 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
AU2014268477A1 (en) 2013-05-24 2015-11-12 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
JP2014232188A (en) 2013-05-29 2014-12-11 コニカミノルタ株式会社 Cellulose acylate film, circularly polarizing plate and image display device
EP3013341A4 (en) 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
RU2708690C2 (en) 2013-08-08 2019-12-11 Галапагос Нв Derivatives of thieno[2,3-c]pyrans as cftr modulators
WO2015036552A1 (en) 2013-09-12 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
JP6564380B2 (en) 2013-09-20 2019-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Compounds for treating prostate cancer
WO2015050984A1 (en) 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
WO2015054337A1 (en) 2013-10-09 2015-04-16 Emory University Heterocyclic coupling catalysts and methods related thereto
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
KR20150062652A (en) 2013-11-29 2015-06-08 삼성전자주식회사 Sonosensitive liposome, a pharmaceutical composition comprising the same and a method of delivering an active agent into a subject using the same
JP6759100B2 (en) 2013-12-30 2020-09-23 ライフサイ ファーマシューティカルズ，インク． Therapeutic inhibitor compound
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
JP2015172005A (en) 2014-03-11 2015-10-01 国立大学法人 東京大学 Method of producing coupling compound by iron catalyst
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
ES2957761T3 (en) 2014-04-15 2024-01-25 Vertex Pharma Pharmaceutical compositions for the treatment of diseases mediated by the cystic fibrosis transmembrane conductance regulator
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
JP5932881B2 (en) * 2014-05-08 2016-06-08 株式会社フジクラ Multi-core fiber and method for producing the multi-core fiber
PL3142701T3 (en) 2014-05-12 2018-11-30 Verona Pharma Plc New treatment
BR112016026378B8 (en) 2014-05-16 2020-06-09 Liqwd Inc method for bleaching hair and using an active agent that is maleic acid to reduce or prevent damage to hair
AU2015264336B2 (en) 2014-05-19 2018-08-30 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds
AU2015269598B2 (en) 2014-06-05 2019-11-14 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
WO2016025448A2 (en) 2014-08-13 2016-02-18 Akeso Biomedical, Inc. Antimicrobial compounds and compositions, and uses thereof
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
SG10201901192TA (en) 2014-09-10 2019-03-28 Epizyme Inc Smyd inhibitors
CN104725628B (en) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group
WO2016050208A1 (en) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Bio-related substance modified by multifunctionalized polyethylene glycol derivative
WO2016050209A1 (en) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Heterofunctionalized polyethylene glycol derivative, preparation method, and bio-related substance
WO2016050210A1 (en) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Multifunctionalized polyethylene glycol derivative and preparation method therefor
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US9573948B2 (en) 2014-10-06 2017-02-21 Flatley Discovery Lab Triazolopyridine compounds and methods for the treatment of cystic fibrosis
CN107250113B (en) 2014-10-07 2019-03-29 弗特克斯药品有限公司 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US20160108406A1 (en) 2014-10-08 2016-04-21 University Of Iowa Research Foundation Method of regulating cftr expression and processing
US20170281612A1 (en) 2014-10-08 2017-10-05 Nivalis Therapeutics, Inc. Methods for the Treatment of Cystic Fibrosis
GB201418892D0 (en) 2014-10-23 2014-12-10 Proqr Therapeutics B V DNA editing
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
BR112017009194A2 (en) 2014-10-31 2017-12-26 Abbvie Sarl substituted tetrahydropyran and method of use
PL3212189T3 (en) 2014-10-31 2021-03-08 AbbVie Overseas S.à r.l. Substituted chromanes and method of use
WO2016086015A1 (en) 2014-11-25 2016-06-02 University Of Rochester Myoglobin-based catalysts for carbene transfer reactions
MA41031A (en) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc CYSTEAMINE-FATTY ACID CONJUGATES AND THEIR USE AS AUTOPHAGIC ACTIVATORS
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
AU2015370463B2 (en) 2014-12-24 2020-12-24 Kither Biotech S.R.L. Novel PI3K gamma inhibitor peptide for treatment of respiratory system diseases
CA2970948A1 (en) 2014-12-31 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
CN105753814A (en) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 Substituted nitrogen heterocyclic derivative and application thereof
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028480A2 (en) 2002-09-30 2004-04-08 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004080972A1 (en) 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
US20060148864A1 (en) 2003-04-11 2006-07-06 Ptc Therapeutics, Inc. 3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof
WO2004091502A2 (en) 2003-04-11 2004-10-28 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds
US20050164973A1 (en) 2003-04-11 2005-07-28 Pct Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US7202262B2 (en) 2003-04-11 2007-04-10 Ptc Therapeutics, Inc. Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
US20060148863A1 (en) 2003-04-11 2006-07-06 Ptc Therapeutics, Inc. Substituted 1,2,4-oxadiazoles, compositions and methods of use
US6992096B2 (en) 2003-04-11 2006-01-31 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20060035943A1 (en) 2003-04-11 2006-02-16 Ptc Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2005035514A2 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
WO2005049018A1 (en) 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
WO2005094374A2 (en) 2004-03-30 2005-10-13 The Regents Of The University Of California Hydrazide-containing cftr inhibitor compounds and uses thereof
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2006044503A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006044682A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044505A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044502A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006099256A2 (en) 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2006101740A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2006127588A2 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2007044560A2 (en) 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20090131492A1 (en) 2006-04-07 2009-05-21 Ruah Sara S Hadida Indole derivatives as CFTR modulators

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ARIDOR M ET AL., NATURE MED., vol. 5, no. 7, 1999, pages 745 - 751
BROSS P. ET AL., HUMAN MUT., vol. 14, 1999, pages 186 - 198
CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369
DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528
DEAN, M. ET AL., CELL, vol. 61, 1990
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
GONZALEZ, J. E., K. OADES ET AL.: "Cell-based assays and instrumentation for screening ion-channel targets", DRUG DISCOV TODAY, vol. 4, no. 9, 1999, pages 431 - 439, XP001026838, DOI: doi:10.1016/S1359-6446(99)01383-5
GONZALEZ, J. E., R. Y. TSIEN: "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer", CHEM BIOL, vol. 4, no. 4, 1997, pages 269 - 77, XP000961796, DOI: doi:10.1016/S1074-5521(97)90070-3
GONZALEZ, J. E., R. Y. TSIEN: "Voltage sensing by fluorescence resonance energy transfer in single cells", BIOPHYS J, vol. 69, no. 4, 1995, pages 1272 - 80, XP000961694
GREGORY, R. J. ET AL., NATURE, vol. 347, 1990, pages 382 - 386
KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451
KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080
LEE R. CHOO-KANG, PAMELA L.: "Zeitlin, Type l, II, IlL IV, and V cystic fibrosis Tansmembrane Conductance Regulator Defects and Opportunities of Therapy", CURRENT OPINION IN PULMONARY MEDICINE, vol. 6, 2000, pages 521 - 529
MORELLO, JP ET AL., TIPS, vol. 21, 2000, pages 466 - 469
PASYK, FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50
QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727
RICH, D. P. ET AL., NATURE, vol. 347, 1990, pages 358 - 362
RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073
RUTISHAUSER, J. ET AL., SWISS MED WKLY, vol. 132, 2002, pages 211 - 222
SHASTRY, B.S. ET AL., NEUROCHEM. INTERNATIONAL, vol. 43, 2003, pages 1 - 7

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP3835297A1 (en) * 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthesis and intermediates of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2014534236A (en) * 2011-11-08 2014-12-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Modifiers for ATP-binding cassette transporters
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9790215B2 (en) 2013-03-13 2017-10-17 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers
US11426407B2 (en) 2014-10-06 2022-08-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10758534B2 (en) 2014-10-06 2020-09-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10689370B2 (en) 2014-12-31 2020-06-23 Auspex Pharmaceuticals, Inc. Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator
US10167278B2 (en) 2014-12-31 2019-01-01 Auspex Pharmaceuticals, Inc. Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
US10751363B2 (en) 2015-03-23 2020-08-25 Algipharma As Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
US10093666B2 (en) 2016-04-13 2018-10-09 Arixa Pharmaceuticals, Inc. Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US11186566B2 (en) 2016-09-30 2021-11-30 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11453655B2 (en) 2016-12-09 2022-09-27 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019010092A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018353A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US11155533B2 (en) 2017-10-19 2021-10-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11179367B2 (en) 2018-02-05 2021-11-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for treating cystic fibrosis
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11866450B2 (en) 2018-02-15 2024-01-09 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020102346A1 (en) 2018-11-14 2020-05-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP4218754A2 (en) 2018-11-14 2023-08-02 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US10875846B2 (en) 2019-01-15 2020-12-29 Apotex Inc. Processes for the preparation of Tezacaftor and intermediates thereof
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
US11591350B2 (en) 2019-08-14 2023-02-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2021030556A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2021030555A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2022032068A1 (en) 2020-08-07 2022-02-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2022076618A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076624A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076620A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076627A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076622A2 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076625A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076629A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022125826A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023150237A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023196429A1 (en) 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US12122788B2 (en) 2023-01-04 2024-10-22 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators

Also Published As

Publication number Publication date
JP6484652B2 (en) 2019-03-13
HK1218419A1 (en) 2017-02-17
CA2797118A1 (en) 2011-10-27
IL236209A0 (en) 2015-01-29
SG184987A1 (en) 2012-11-29
EP3381899A1 (en) 2018-10-03
RU2012149691A (en) 2014-05-27
TWI561518B (en) 2016-12-11
AU2016202569A1 (en) 2016-05-19
IL222539A0 (en) 2012-12-31
TW201636337A (en) 2016-10-16
SG10201505700QA (en) 2015-08-28
ES2858351T3 (en) 2021-09-30
EP2560954A2 (en) 2013-02-27
KR20160045943A (en) 2016-04-27
US20210238158A1 (en) 2021-08-05
KR20190061096A (en) 2019-06-04
TW201204715A (en) 2012-02-01
EP2560954B1 (en) 2016-10-05
IL268953B (en) 2020-05-31
BR112012027056A2 (en) 2017-08-08
CA2797118C (en) 2021-03-30
US20130324743A1 (en) 2013-12-05
AU2016202569B2 (en) 2018-01-04
MX353408B (en) 2018-01-11
IL268953A (en) 2019-10-31
BR112012027056B8 (en) 2021-09-08
TW201612173A (en) 2016-04-01
NZ734535A (en) 2019-05-31
CN103038214B (en) 2015-09-30
RU2569678C2 (en) 2015-11-27
CN103038214A (en) 2013-04-10
US20150218122A1 (en) 2015-08-06
MX342288B (en) 2016-09-23
JP2017071650A (en) 2017-04-13
US9035072B2 (en) 2015-05-19
BR112012027056B1 (en) 2021-08-24
JP2019031570A (en) 2019-02-28
EP3381899B1 (en) 2021-01-06
US20190210991A1 (en) 2019-07-11
RU2745977C2 (en) 2021-04-05
SG10201913594UA (en) 2020-02-27
TWI620744B (en) 2018-04-11
NZ603721A (en) 2014-11-28
WO2011133751A9 (en) 2012-02-16
KR101984225B1 (en) 2019-05-30
JP6714673B2 (en) 2020-06-24
CN105130948A (en) 2015-12-09
RU2015145784A (en) 2019-01-11
TWI518082B (en) 2016-01-21
MX2012012204A (en) 2012-12-05
RU2015145784A3 (en) 2019-04-29
CA3108488A1 (en) 2011-10-27
AU2011242712B2 (en) 2016-01-28
AR081333A1 (en) 2012-08-08
KR20130056244A (en) 2013-05-29
ES2608474T3 (en) 2017-04-11
WO2011133751A3 (en) 2012-01-12
EP3045452A1 (en) 2016-07-20
US10071979B2 (en) 2018-09-11
JP2015166382A (en) 2015-09-24
AU2011242712A1 (en) 2012-11-08
JP2013525371A (en) 2013-06-20
IL236209B (en) 2019-09-26
HK1225721A1 (en) 2017-09-15

Similar Documents

Publication Publication Date Title
AU2016202569B2 (en) Process of producing cycloalkylcarboxamido-indole compounds
EP2555754B1 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2015221470B2 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180031319.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11729195

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013506299

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/012204

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2797118

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3253/KOLNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011242712

Country of ref document: AU

Date of ref document: 20110421

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127030452

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012149691

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011729195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011729195

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012027056

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 13642642

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112012027056

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121022